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1. Introduction
The British Association for Psychopharmacology (BAP; www.
bap.org.uk) aims to advance education and research in the sci-
ence and practice of psychopharmacology by arranging scientific 
meetings, fostering research and teaching, encouraging publica-
tion of research results, and providing guidance and information 
on matters relevant to psychopharmacology. As part of this 
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process the BAP has developed and periodically revised a series 
of consensus statements on the use of psychotropic drugs in 
patients with psychiatric and other disorders, with an emphasis 
on making concise and realistic recommendations based on a 
review of the evidence [IV] (Anderson et al., 2000, 2008; Barnes 
and Schizophrenia Consensus Group of British Association for 
Psychopharmacology, 2011; Burns and O’Brien., 2006; Goodwin, 
2003, 2005; Goodwin et al., 2008; Lingford-Hughes et al., 2004, 
2012; National Institute for Health and Clinical Excellence, 
2011; O’Brien and Burns, 2010; Nutt et al., 2006; Wilson et al., 
2010).
Anxiety symptoms and disorders are common in community 
settings, and in primary and secondary medical care. The per-
sonal and societal burden associated with anxiety disorders is 
considerable, but many people who might benefit from treatment 
are not recognised or treated. Likely factors in this sub-optimal 
management include the range of different anxiety disorders, 
their co-morbidity with other disorders (particularly mood disor-
ders), a widespread lack of awareness of anxiety disorders by 
affected individuals and health practitioners, and the low confi-
dence of many practitioners in their management. Conversely, 
some patients with only mild or transient anxiety symptoms 
receive unnecessary or inappropriate treatment. Given the con-
siderable room for improvement, the BAP previously produced 
evidence-based guidelines for the pharmacological treatment of 
anxiety disorders [IV] (Baldwin et al., 2005): this revision of 
those guidelines provides an update on key steps in diagnosis and 
treatment.
2. Caveats
Clinical guidelines are systematically derived statements that aim 
to inform treatment decisions in clinical care. Recommendations 
are graded according to the strength of evidence, and whenever 
possible are derived from the findings of systematic reviews and 
randomised controlled trials. Principal recommendations apply 
to the management of ‘typical’ patients and hence apply much of 
the time: we therefore use expressions such as ‘clinicians should 
consider…’ in the summary boxes. But there are many patients 
and many clinical decision points where slavish adherence to 
guideline recommendations may be unhelpful and possibly 
harmful. In situations where the evidence is weaker we summa-
rise potential management options, recognising that their imple-
mentation depends upon clinician experience, patient clinical 
features and preference, and local circumstance [IV] (Haynes 
et al., 2002). Some of our recommendations may be regarded as 
standards of clinical care that are largely driven by custom and 
practice: these are ‘standards’ which are intended to be applied 
routinely. 
There is often a tension between existing established clinical 
practice and the possible implications of new research findings 
for changing practice. Existing practice may be accepted on the 
basis of prolonged clinical experience but limited good quality 
evidence: new treatments may have proven superiority to pla-
cebo in methodologically robust randomised controlled trials, but 
lack comparator data against ‘established’ treatments. We attempt 
to strike a balance between the risks of advocating specific novel 
treatment recommendations that may prove premature and adher-
ing to established routines when the evidence supporting them is 
questionable.
3. Process for achieving consensus
The revision of the original BAP guidelines started in February 
2011, with a consensus meeting attended by experts in the field 
and representatives of patient groups (all who attended are named 
in the acknowledgments). Brief presentations were made on key 
areas, with an emphasis on systematic reviews and randomised 
controlled trials. Each presentation was followed by discussion, 
to identify areas of consensus or uncertainty.
A literature review was then performed to ascertain the valid-
ity of the consensus points. Logistical factors made it impossible 
to perform a systematic review of all possible data from primary 
sources. Existing systematic reviews and randomised controlled 
trials were identified from MEDLINE and EMBASE searches 
and from the Cochrane Database, as well as from recent previous 
guidelines and reviews [IV] (Baldwin et al., 2011b; Bandelow 
et al., 2008a; Batelaan et al., 2012; Blanco et al., 2013; Fineberg 
et al., 2012; Ipser and Stein, 2012), through cross-referencing, 
and through discussion with experts in the field. We also drew on 
recent guidelines for generalised anxiety disorder, panic disorder, 
social anxiety disorder, post-traumatic stress disorder and obses-
sive-compulsive disorder developed by the National Institute for 
Health and Clinical Excellence (2005, 2011a, 2011b, 2013).
Particular attention was paid to research findings which had 
appeared since 2005, the year of publication of the original 
guidelines. Draft versions of the consensus statement, with rec-
ommendations based on the level of supporting evidence, were 
circulated repeatedly to the presenters and other participants and 
their comments were incorporated into the final version of the 
guidelines. Given the range and depth of the subject area it was 
not possible for all participants in the wider group to achieve full 
consensus on all points.
4. Levels of evidence and strength of 
recommendations
The categories of evidence for causal relationships and the grad-
ing of recommendations have their origin in the methodology of 
the North of England Evidence-Based Guideline Development 
Project undertaken by the Centre for Health Services Research, 
University of Newcastle upon Tyne and the Centre for Health 
Economics, University of York [IV] (Shekelle et al., 1999). 
Given current debates about their competing merits, we have 
accorded a similar ‘level’ (‘I’) in the hierarchy of evidence to the 
findings of systematic reviews and to the results of randomised 
controlled trials, noting the evidence source which is available 
for each statement and recommendation (Table 1). Weaker levels 
of recommendations do not necessarily imply a reduced level of 
clinical importance. As in some previous guidelines we have 
included a category denoted as ‘S’ (representing a standard of 
care), for a recommendation that reflects important consensus on 
good clinical practice rather than on empirical evidence.
5. Aim and scope of the guidelines
We hope the guidelines will prove relevant to most doctors treat-
ing patients with anxiety and related disorders, in primary, sec-
ondary and tertiary medical care settings. Each of the principal 
disorders – generalised anxiety disorder, panic disorder, specific 
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(or simple) phobia, social anxiety disorder (also known as social 
phobia), post-traumatic stress disorder, and obsessive-compulsive 
disorder – is considered in turn, following key steps in manage-
ment (acute treatment; longer-term treatment; combination with 
psychological approaches; treatment resistance). The continued 
inclusion or otherwise of obsessive-compulsive disorder within 
the broad category of anxiety disorders is the subject of continu-
ing debate, given evidence of its dissimilarity from other anxiety 
disorders and its resemblance to other conditions characterised by 
compulsivity and impulsivity: but the principles of pharmacologi-
cal treatment of anxiety disorders and obsessive-compulsive dis-
order share many common features, and so we have chosen to 
retain obsessive-compulsive disorder within these guidelines. We 
also include separation anxiety disorder, given its inclusion within 
anxiety disorders in the Diagnostic and Statistical Manual (DSM-
5) (American Psychiatric Association, 2013), though evidence 
relating to its treatment in adults is at present very sparse. We also 
summarise the evidence for treatment of patients with health anxi-
ety (‘illness anxiety disorder’), partly because of the overlap in 
clinical features with those of generalised anxiety disorder.
We expect the guidelines will be most useful in informing 
decisions in primary and secondary care, regarding pharmaco-
logical treatment in patients aged between 18–65 years. The 
nature and prevalence of anxiety disorders changes during child-
hood and adolescence and the mean age of onset in adult patients 
varies between anxiety disorders. Most adults with anxiety disor-
ders report an onset of symptoms in childhood or adolescence 
(Jones, 2013; Kessler et al., 2005), and some recommendations 
(for example those pertaining to obsessive-compulsive disorder 
and social phobia) will therefore be potentially applicable to ado-
lescent patients. Similarly the recommendations are also likely to 
be pertinent to elderly patients although we did not specifically 
review evidence in those aged over 65 years.
6. Epidemiology of anxiety symptoms 
and disorders
Anxiety symptoms are common in the general population and 
in primary and secondary medical care. Symptoms may be 
mild, transient and without associated impairment in social and 
occupational function, but many patients are troubled by severe 
and persistent symptoms that cause significant personal dis-
tress, impair function and reduce quality of life. To meet the 
diagnosis of an anxiety disorder, patients have to experience a 
certain number of symptoms for more than a minimum speci-
fied period, the symptoms causing significant personal dis-
tress, with an associated impairment in everyday function. 
Most research in the field has been based on the diagnostic 
categories for anxiety disorders in the fourth edition of the 
Diagnostic and Statistical Manual (DSM-IV) [IV] (American 
Psychiatric Association, 1994) which are broadly similar to 
those in the tenth edition of the International Classification of 
Diseases (ICD-10) [IV] (World Health Organisation, 1992). 
The DSM system has recently been revised, and it is uncertain 
whether the approach to anxiety disorders within ‘ICD-11’ will 
differ substantially from ICD-10 or DSM-5.
We give simplified versions of the principal clinical features 
of the anxiety disorders, post-traumatic stress disorder and obses-
sive-compulsive disorder in Table 2: a simple algorithm for ini-
tial delineation of anxiety and depressive symptoms into disorders 
is suggested in Figure 1.
Epidemiological studies in the general population indicate 
that when taken together anxiety disorders have a 12-month 
period prevalence of approximately 14% [I] (Wittchen et al., 
2011) (see Table 3), and a lifetime prevalence of approximately 
21% [I] (Wittchen and Jacobi, 2005). Individual disorders are 
less frequent, with estimated 12-month prevalence rates rang-
ing between 0.7% (obsessive-compulsive disorder) and 6.4% 
(specific phobia), and estimated lifetime prevalence rates 
between 0.8% (obsessive-compulsive disorder) and 13.2% 
(specific phobia). The age and sex distribution of individual 
disorders varies: for example, specific phobias are markedly 
more common in women than men across all age bands, whereas 
panic disorder is almost as frequent in men and women in mid-
dle age. Despite this variation within individual anxiety disor-
ders, the pattern for all disorders taken together is fairly constant 
with an overall female: male ratio of approximately 2:1 across 
the age range.
Table 1. Levels of evidence and strength of recommendations.
Categories of evidence relevant to treatment
I [M] Evidence from meta-analysis of randomised double-blind placebo-controlled trials
I [PCT] Evidence from at least one randomised double-blind placebo-controlled trial
II Evidence from at least one randomised double-blind comparator-controlled trial (without placebo)
III Evidence from non-experimental descriptive studies
IV Evidence from expert committee reports or opinions and/or clinical experience of respected authorities
Categories of evidence relevant to observational findings and associations
I Evidence from large representative population samples
II Evidence from small, well designed but not necessarily representative samples
III Evidence from non-representative surveys, case reports
IV Evidence from expert committee reports or opinions and/or clinical experience of respected authorities
Strength of recommendations
A Directly based on category I evidence (either I [M] or I [PCT])
B Directly based on category II evidence or an extrapolated recommendation from category I evidence
C Directly based on category III evidence or an extrapolated recommendation from category I or II evidence
D Directly based on category IV evidence or an extrapolated recommendation from other categories
S Standard of clinical care
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6.1. Course of anxiety symptoms and 
disorders
Longitudinal studies in community samples indicate that many 
individuals with anxiety symptoms that are below the threshold 
for an anxiety disorder diagnosis experience an episodic condi-
tion with prolonged periods of remission: reappearance or wors-
ening of symptoms being associated with adverse life events and 
other psychosocial stressors. By contrast, follow-up studies in 
patient groups demonstrate that anxiety disorders tend to run a 
chronic course, often over many years, with symptoms fluctuat-
ing in severity between periods of remission and relapse, the 
course of illness varying between disorders [II] (Bruce et al., 
2005).
Generalised anxiety disorder tends to run a waxing and wan-
ing course in non-clinical samples [I] (Angst et al., 2009), and a 
prolonged course in primary care [I] (Rodriguez et al., 2006): but 
may also ‘switch’ to other diagnoses particularly depression and 
somatoform disorders [II] (Rubio and Lopez-Ibor, 2007a). Social 
anxiety disorder tends to run a chronic course in primary [I] 
(Beard et al., 2010) and secondary medical care settings [II] 
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Figure 1. Suggested scheme for exploring a suspected anxiety disorder. 
GAD: generalised anxiety disorder; OCD: obsessive-compulsive disorder; 
PTSD: post-traumatic stress disorder.
Table 2. Principal clinical features of the anxiety disorders, post-traumatic stress disorder, and obsessive-compulsive disorder.
Generalised anxiety disorder
Generalised anxiety disorder is characterised by excessive and inappropriate worrying that is persistent (lasting more than a few months) and not 
restricted to particular circumstances. Patients have physical anxiety symptoms and key psychological symptoms (restlessness, fatigue, difficulty 
concentrating, irritability, muscle tension and disturbed sleep). Generalised anxiety disorder is often co-morbid with major depression, panic disor-
der, phobic anxiety disorders, health anxiety and obsessive-compulsive disorder.
Panic disorder (with or without agoraphobia)
Panic disorder is characterised by recurrent unexpected surges of severe anxiety (‘panic attacks’), with varying degrees of anticipatory anxi-
ety between attacks. Panic attacks are discrete periods of intense fear or discomfort, accompanied by multiple physical or psychological anxiety 
symptoms. Panic attacks typically reach their peak within 10 min and last around 30–45 min. Most patients develop a fear of having further panic 
attacks. Around two-thirds of patients with panic disorder develop agoraphobia, defined as fear in places or situations from which escape might be 
difficult or in which help might not be available, in the event of having a panic attack. These situations include being in a crowd, being outside 
the home, or using public transport: they are either avoided or endured with significant personal distress.
Social phobia (social anxiety disorder)
Social phobia is characterised by a marked, persistent and unreasonable fear of being observed or evaluated negatively by other people, in social 
or performance situations, which is associated with physical and psychological anxiety symptoms. Feared situations (such as speaking to unfamiliar 
people or eating in public) are either avoided or are endured with significant distress.
Specific phobia
Specific, simple or isolated phobia is characterised by excessive or unreasonable fear of (and restricted to) single people, animals, objects, or situa-
tions (for example, dentists, spiders, lifts, flying, seeing blood) which are either avoided or are endured with significant personal distress.
Separation anxiety disorder
Separation anxiety disorder is characterised by fear or anxiety concerning separation from those to whom an individual is attached: common 
features include excessive distress when experiencing or anticipating separation from home, and persistent and excessive worries about potential 
harms to attachment figures or untoward events that might result in separation.
Post-traumatic stress disorder
Post-traumatic stress disorder is characterised by a history of exposure to trauma (actual or threatened death, serious injury, or threats to the 
physical integrity of the self or others) with a response of intense fear, helplessness or horror; with the later development of intrusive symptoms 
(such as recollections, flashbacks or dreams), avoidance symptoms (for example efforts to avoid activities or thoughts associated with the trauma), 
negative alterations in cognitions and mood, and hyper-arousal symptoms (including disturbed sleep, hypervigilance and an exaggerated startle 
response).
Obsessive-compulsive disorder
Obsessive-compulsive disorder is characterised by recurrent obsessive ruminations, images or impulses, and/or recurrent physical or mental rituals; 
which are distressing, time-consuming and cause interference with social and occupational function. Common obsessions relate to contamination, 
accidents, and religious or sexual matters; common rituals include washing, checking, cleaning, counting and touching.
Illness anxiety disorder
A somatic symptom related disorder characterised by excessive or disproportionate preoccupations with having or acquiring a serious illness, with 
excessive health-related behaviours and high levels of alarm about personal health status.
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(Bruce et al., 2005; Ramsawh et al., 2009). For panic disorder, 
prospective studies reveal high degrees of symptom chronicity 
[I] (Batelaan et al., 2010b), relapse after remission [I] (Batelaan 
et al., 2010a), and ‘switching’ to other diagnoses [II] (Rubio and 
Lopez-Ibor, 2007b). Childhood separation anxiety disorder often 
resolves with entry into adolescence [I] (Copeland et al., 2014). 
Retrospective longitudinal studies in obsessive-compulsive dis-
order suggest a very poor outcome, though prospective studies in 
non-clinical [I] (Fineberg et al., 2013) and clinical samples [II] 
(Eisen et al., 2010; Kempe et al., 2007) indicate a more favoura-
ble prognosis. Cohort studies which have examined the course of 
symptoms following traumatic experiences suggest that post-
traumatic stress disorder emerges in only a minority of affected 
individuals (for example, [II] Mayou et al., 2001) the course of 
established post-traumatic stress disorder is not established, 
though a chronic course was seen in almost one-half of adoles-
cents and young adults [I] (Perkonigg et al., 2005).
Recommendations: increased awareness of anxiety 
disorders
● Become familiar with the main features of the anxiety 
disorders, post-traumatic stress disorder and obsessive-
compulsive disorder: and with the main symptoms 
which distinguish between them [S]
● Develop systematic questions to ask about the nature, 
severity, duration, distress and associated impairment 
in patients with anxiety symptoms, to decide whether 
an anxiety disorder, post-traumatic stress disorder or 
obsessive-compulsive disorder is present [S]
● Become familiar with the fluctuating nature of symp-
toms in patients with anxiety disorders, and with the ten-
dency for symptoms to change in nature over time [S]
6.2. Co-existing psychological symptoms and 
co-morbid mental disorders
Anxiety symptoms often co-exist with other psychological symp-
toms, especially depressive symptoms, which are particularly 
frequent among those individuals with more severe anxiety 
symptoms. Cross-sectional studies in European community and 
clinical settings [I] (Fehm et al., 2005; Goodwin, 2005; Lieb et al., 
2005) and in UK primary medical care [I] (Nease and Aikens, 
2003) reveal a significant correlation between measures of anxi-
ety and depressive symptom severity. Many patients with anxiety 
disorders also simultaneously fulfil diagnostic criteria for another 
disorder, this pattern typically being named ‘co-morbidity’. High 
levels of co-morbidity are seen between the anxiety disorders, 
and with major depression [I] (Wittchen and Jacobi, 2005), bipo-
lar disorder [II] (Gaudiano and Miller, 2005; Henry et al., 2003), 
schizophrenia (IV) (Buckley et al., 2009) substance misuse 
(Castle, 2008; Crippa et al., 2009; Robinson et al., 2009; 
Ziedonis et al., 2008) and physical illness [IV] (Davies et al., 
2007; Roy-Byrne et al., 2008).
The presence of a comorbid anxiety disorder is associated 
with both a longer time to recovery and with a greater risk of end-
ing treatment prematurely in patients with major depression [II] 
(Brown et al., 1996). An early systematic review found that 
patients with comorbid conditions generally had worse outcomes 
than those with anxiety disorder or depressive disorder alone [I] 
(Emmanuel et al., 1998). This is supported by the findings of the 
US National Comorbidity Survey which demonstrated that indi-
viduals with comorbid generalised anxiety disorder and major 
depression were significantly more likely to remain symptomatic 
than individuals with depression or generalised anxiety disorder 
alone [I] (Kessler et al., 2008).
Detection of co-morbid depression can sometimes lead to 
simultaneous recognition of an underlying primary anxiety disor-
der. For example, a French primary care study of the prevalence, 
recognition and treatment of social phobia found that detection 
rates were increased in the presence of comorbid depression 
(66%, compared with 53% in those without depression) [I] 
(Weiller et al., 1996). However the presence of a seemingly more 
pressing comorbid condition can result in sub-optimal treatment 
for the anxiety disorder. Data from a United Kingdom general 
practice cluster randomised controlled trial of the impact of men-
tal health guidelines, which found that only 54% of patients with 
a ‘common mental disorder’ (depression or anxiety) were offered 
active treatment, revealed that patients with anxiety or mixed 
anxiety-depression were significantly less likely to be offered 
Table 3. Twelve-month prevalence of anxiety disorders within the European Union.
Diagnosis (DSM-IV) Inter-quartile range (%) Best estimate (%) Number affected (millions)a
Anxiety disorders Not applicableb 14.0 61.5
Panic disorder 0.4–2.0 1.8 7.9
Agoraphobia 0.4–2.0 2.0 8.8
Social anxiety disorder 1.1–4.4 2.3 10.1
Specific phobias 3.4–7.1 6.4 22.7
Generalised anxiety disorder 0.6–2.2 1.7–3.4c 8.9
Obsessive-compulsive disorder 0.5–1.1 0.7 2.9
Post-traumatic stress disorder 0.7–2.5 1.1–2.9d 7.7
aAccording to Eurostat Directorate General of European Commission (Eurostat 2010) for the age groups used.
bAggregate data from single study. 95% confidence interval, 13.4–15.6%.
cAge range 14–65 years, 1.7%; age 65+ years, 3.4%.
dAge range 14–34 years, 2.9%; age range 35–65 years, 1.3%; age 66+ years, 1.1%.
Best estimates represent consensus view of experts on most probable estimate from identified range. Full data available in Wittchen et al. (2011). DSM-IV refers to the 
Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association (1994).
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treatment than patients with depression alone [I] (Hyde et al., 
2005). Analysis of a Dutch primary care database involving 
patients with a newly diagnosed anxiety disorder found that ben-
zodiazepines were significantly more frequently prescribed in 
patients with psychiatric comorbid conditions, and antidepres-
sants significantly more frequently prescribed in patients with 
comorbid physical illness: in both forms of comorbidity, the pre-
scription pattern of benzodiazepines was inconsistent with cur-
rent guideline recommendations [I] (Smolders et al., 2007).
The presence of marked co-existing depressive symptoms is 
an important consideration in treatment decisions. Where anxiety 
symptoms are present within the context of a depressive disorder, 
antidepressant drug treatment is often effective in reducing anxi-
ety (IV) (Anderson et al., 2008). Where depression follows or is 
comorbid with an anxiety disorder it is generally indicative of 
greater severity and associated with poorer prognosis (II) (Albus 
and Scheibe, 1993; Brown et al., 1995; Cowley et al., 1996; 
Erwin et al., 2002; Martinsen et al., 1998; Rief et al., 2000; 
Shalev et al., 1998). Clinical practice has usually been to direct 
treatment towards the depressive disorder in the first instance, 
choosing treatments that also have action against the symptoms 
of the anxiety disorder: though some guidance notes that when a 
patient has an anxiety disorder and comorbid depression or 
depressive symptoms, treating the anxiety disorder first should 
also be considered, as effective treatment of the anxiety disorder 
will often improve the depression or depressive symptoms 
(National Institute for Health and Clinical Excellence, 2011).
Recommendations: enquiring about coexisting symp-
toms and comorbid disorders
● Check for anxiety symptoms in patients presenting 
with symptoms of other mental disorders, including 
depression, bipolar disorder, psychosis and substance 
misuse [A]
● Remember that coexisting depressive symptoms in 
patients with anxiety disorders are associated with 
greater functional impairment and a longer duration of 
illness [B]
● Assess for comorbid depression and treat if depressive 
symptoms are of more than mild intensity [S]
7. Detection of anxiety symptoms in 
primary medical care settings
Within the setting of primary medical care (general practice), 
most patients with anxiety or depression have relatively mild 
and transient symptoms, which tend to resolve without the need 
for intervention: but many have severe, persistent and disabling 
symptoms, which are likely to benefit from psychological or 
pharmacological treatment. However, many patients with anxi-
ety and depressive symptoms do not present to primary medical 
care services [I] (Andrews and Carter, 2001; Roness et al., 
2005). Even when patients do consult their general practitioner, 
anxiety symptoms are usually not their presenting complaints. 
The general practitioner therefore faces a significant challenge, 
in detecting the sample of patients most in need of treatment, 
from among the wider group, in many of whom intervention 
may be unnecessary.
The limited detection of anxiety disorders in primary care has 
been observed in multiple countries over many years. A Dutch 
study found a low (47%) rate of detection of anxiety and depres-
sion, recognition being more likely in anxiety disorders of shorter 
duration [I] (Ormel et al., 1991). A German study, in which 5.3% 
of patients fulfilled diagnostic criteria for generalised anxiety 
disorder, and 1.6% for comorbid major depressive episode and 
generalised anxiety disorder, found that whilst the majority (over 
70%) of affected individuals were recognised as having clinically 
significant emotional problems, accurate diagnosis was less com-
mon (34.4% for generalised anxiety disorder) [I] (Wittchen et al., 
2002). A United States investigation of older patients with gener-
alised anxiety disorder found low rates of recording of anxiety 
symptoms (34%) or anxiety disorder (9%) despite much use of 
health services [I] (Calleo et al., 2009). A Canadian study found 
the majority of ‘cases’ of anxiety disorder diagnosed through a 
structured clinical interview did not have a recorded diagnosis 
(generalised anxiety disorder, 71.0%; panic disorder, 85.8%; 
social anxiety disorder, 97.8%) [I] (Vermani et al., 2011).
Limited recognition is partly related to difficulty in discussing 
emotional difficulties: many patients do not express emotional 
symptoms and many doctors find it hard to raise concerns about 
potential psychological distress. A United Kingdom general prac-
tice survey involving patients whose questionnaire scores indi-
cated likely psychiatric ‘caseness’ found the vast majority had 
not mentioned emotional problems in the consultation, mainly 
through fears of either being unable to cope with the ensuing dis-
tress or of embarrassment, or through not wishing to trouble their 
doctor: but many also felt there would be either insufficient time, 
or the doctors could do nothing to help [II] (Cape and McCulloch, 
1999). A United States primary care study found that doctors who 
were more sensitive to non-verbal communications were more 
likely to make diagnoses; but those who tended to ‘blame’ 
patients made fewer psychological assessments, and were less 
accurate in detecting distress [II] (Robbins et al., 1994).
Fortunately general practice is structured in such a way that 
many patients present repeatedly, which provides an opportunity 
for recognition of symptoms at subsequent consultations, if an 
anxiety disorder is not detected at the first visit. In a United 
Kingdom longitudinal study of the detection of depression and 
anxiety which found that many ‘cases’ were not detected at the 
initial appointment, the vast majority of undetected cases of 
depression or anxiety were recognised at follow-up [I] (Kessler 
et al., 2002). A Dutch primary care practice survey found that 
patients with an anxiety disorder were less likely to be diagnosed 
than patients with a depressive episode, but the likelihood of 
diagnosis in both conditions increased with the number of con-
sultations, and the expression of more severe psychological 
symptoms [I] (Verhaak et al., 2006).
Recommendations: increasing skills in detecting anxi-
ety symptoms
● Remember that many patients are either reluctant to 
present with psychological symptoms or find it hard 
discuss emotional problems [A]
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● Be sensitive to non-verbal expression of psychological 
distress [B]
● Use the opportunity provided by repeated consulta-
tions in primary care to ask follow-up questions about 
possible anxiety symptoms when these were suspected 
but not established at earlier appointments [A]
● Routine screening of all patients for the presence of 
anxiety symptoms is not recommended [A]
8. Screening for anxiety disorders in 
primary care settings
In theory, patients and health professionals might benefit from 
the use of screening tools for detecting anxiety disorders, which 
can lead to discussion of psychological symptoms at both the 
index and subsequent appointments. A Danish primary care study 
of the potential value of screening for common mental disorders 
found that disclosure of scores on screening questionnaires 
increased the recognition of mental disorders by doctors with 
moderate or low recognition rates; and also resulted in increased 
discussion of psychological concerns and planned follow-up con-
sultations in patients who had ‘screened positive’ [I] (Christensen 
et al., 2005). However, use of screening questionnaires needs to 
be accompanied by other changes in practice structure, and it is 
uncertain whether routine screening and disclosure of ‘screened 
positive’ patients with anxiety disorders leads to improved clini-
cal outcomes. An educational intervention involving this design, 
among United States primary care patients found no evidence for 
an improvement in patient outcomes [I] (Mathias et al., 1994).
The criteria for diagnosing psychiatric disorders are mainly 
from clinical observations in psychiatric outpatients and inpa-
tients and so may not be appropriate for routine use in screening 
for common mental disorders, among the more mildly ill 
patients in primary care. Primary care doctors often have reser-
vations about the usefulness of DSM-IV criteria for diagnosis in 
primary care, and many of their patients are reluctant to accept 
any offered diagnoses or undergo psychotropic drug treatment 
[II] (Van Rijswijk et al., 2009). Although general practitioners 
sometimes find using screening questionnaires to be trouble-
some within a standard consultation, patients do not object to 
completing them [II] (Leydon et al., 2011). The use of question-
naires for detecting and following up patients with depressive 
symptoms has become part of routine primary care practice in 
the United Kingdom, suggesting that use of a similar question-
naire for detecting anxiety disorders is feasible in practice [IV] 
(Buszewicz and Chew-Graham, 2011).
9. Increasing awareness of anxiety 
disorders in particular patient 
populations
When compared with the general population, anxiety disorders 
are more common among patients with other mental disorders, 
with chronic physical illness, and in certain demographic groups. 
Patients with long-standing socioeconomic problems, and those 
from certain ethnic populations, may be at greater risk of receiv-
ing sub-optimal care and treatment. A Dutch primary care 
investigation, which included a nested case-control study of care 
received by patients with or without psychosocial problems, 
found that individuals with associated problems were signifi-
cantly more likely to receive benzodiazepines and less likely 
to receive antidepressants: which may have contributed to 
their poorer outcomes [I] (Van Rijswijk et al., 2006). A cross-
sectional study of anxiety and depressive symptoms in Australian 
family practices found that unemployed patients, when com-
pared to employed patients, were significantly more likely to 
report affective symptoms, to have greater symptom severity, to 
have previously undergone treatment and to be prescribed psy-
chotropic medication: but were no more likely to be referred to 
mental health services than were employed patients [I] (Comino 
et al., 2000).
Data from the United States indicate that black and Hispanic 
patients were less likely than white patients to receive care for 
depression and anxiety, or to receive antidepressant prescriptions 
(and for Hispanic patients, to undergo counselling) in primary 
care; and black patients were less likely than white patients to 
receive antidepressant prescriptions from a psychiatrist [II] 
(Lagomasino et al., 2011). Similar discrepancies were seen in a 
treatment review among United States primary care patients with 
anxiety disorders, where ‘non-white’ individuals were signifi-
cantly less likely to receive treatment [II] (Weisberg et al., 2007). 
This situation may not necessarily apply in all countries, as a 
Dutch general practice study of the quality of care for anxiety and 
depression across ethnic minority groups found that all groups 
(with the exception of individuals originating from Surinam and 
the Antilles) were as likely to receive guideline-concordant medi-
cal care [I] (Fassaert et al., 2010).
Recommendations: paying particular attention to  
certain patient groups
● Remember that anxiety symptoms tend to persist 
longer in patients who are experiencing long-standing 
socioeconomic difficulties [B]
● Ensure that the presence of socioeconomic disadvan-
tage or membership of a minority ethnic group among 
patients in your practice is not associated with a 
reduced chance of their undergoing evidence-based 
pharmacological or psychological treatment [S]
10. Identifying which patients with 
anxiety disorders should undergo 
treatment
Many anxious individuals have mild symptoms of recent onset 
that are associated with stressful life events or troublesome situ-
ations, which will often improve without needing specific treat-
ment. However, the chronic nature and significant associated 
disability of anxiety disorders means that most patients who fulfil 
the diagnostic criteria for an anxiety disorder – in terms of sever-
ity, duration, distress and impairment – are likely to benefit from 
some form of treatment, whether this is psychological or pharma-
cological. The need for treatment is influenced by the intensity 
and duration of illness, the impact of symptoms on everyday life, 
the presence of co-existing depressive symptoms and comorbid 
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disorders, and the presence of concomitant medication; together 
with other features such as a good response to, or poor tolerabil-
ity of, previous treatments. The choice of a particular treatment 
should be influenced by the supporting evidence base, by patient 
characteristics (such as co-morbid physical illness, previous 
response, or treatment contraindications), the preferences of 
patients and experience of doctors, and the local availability of 
any proposed intervention [IV] (Haynes et al., 2002).
However, many patients with anxiety disorders who might 
benefit from treatment do not receive it. A United States longitu-
dinal primary care study of the use of health services by patients 
with panic disorder found that 64% had undergone some form of 
intervention over 4–10 months, but only 22% had been given 
appropriate pharmacological treatment, and only 12% had 
received appropriate psychological treatment [II] (Roy-Byrne 
et al., 1999). The quality of treatment in those who do receive it 
may be enhanced through making an accurate diagnosis and by 
regular monitoring of progress. Another United States primary 
care study of the treatment of patients with panic disorder found 
that inadequate dosage and insufficient duration of treatment 
were both common, and suggested that enhanced patient educa-
tion and an increased frequency of appointments would be more 
likely to facilitate adequate treatment than would physician edu-
cation [II] (Roy-Byrne et al., 2002). A study of adherence to evi-
dence-based guidelines for depression and anxiety disorders 
within the setting of Dutch primary medical care found that only 
27% of patients with anxiety disorders received guideline-
consistent care: symptom severity had no influence on adher-
ence, but documentation of a diagnosis by the general practitioner 
significantly increased the likelihood of receiving guideline-
consistent care [I] (Smolders et al., 2009).
Media reports in many countries have raised concerns about 
the ‘medicalisation’ of anxiety, shyness, worrying and adjust-
ment to trauma, and about the inappropriate prescribing of psy-
chotropic drugs to patients who are experiencing life stresses or 
situational problems. This may be a factor in some settings, 
though most studies find a low level of inappropriate prescribing 
and a high level of unmet need. For example, a Norwegian pri-
mary care study involving over 1300 patients found some of evi-
dence of ‘overtreatment’ (including inappropriate counselling, 
prescription of psychotropic medication, or specialist referral) in 
11% of individuals without a formal psychiatric diagnosis, but 
also found substantial rates of ‘under-treatment’ for individuals 
with the diagnoses of major depressive episode (49%) or gener-
alised anxiety disorder (64%) [I] (Olsson et al., 2006).
Recommendations: deciding when and which treat-
ment is required
● Assess the severity and duration of anxiety symptoms, 
and the associated distress and impairment, when 
deciding which patients should be offered pharmaco-
logical or psychological treatment [S]
● Remember to ask about coexisting depressive symp-
toms and other potential comorbid disorders [S]
● Consider other factors such as the presence of physical 
illness, current concomitant medication, and a history 
of good response to, or poor tolerability of, previous 
treatments [S]
● Record the diagnosis and review this at subsequent 
appointments [A]
● The choice of a particular treatment should be influ-
enced by the supporting evidence base, by clinical 
characteristics (such as treatment contraindications and 
expected impact of potential side effects), the prefer-
ences of patients, personal experience, and the local 
availability of any proposed intervention[S]
11. Anticipating common concerns 
about potential adverse effects of 
psychotropic drugs
Many patients experience unwanted and distressing adverse 
effects of psychotropic drug treatment, such as sexual dysfunc-
tion with selective serotonin reuptake inhibitors (SSRIs), exces-
sive perspiration with serotonin-noradrenaline reuptake inhibitors 
(SNRIs), drowsiness with pregabalin and the benzodiazepines, or 
weight gain with antipsychotic drugs. Others fear developing a 
tolerance or becoming dependent on medication, and so are 
reluctant to start, let alone continue, pharmacological treatment. 
In addition, many patients and health professionals and some 
commentators consider pharmacological intervention to be a 
merely symptomatic and not a definitive treatment. For these rea-
sons, many of those who might benefit from treatment do not 
receive it, and many of those who do undergo treatment stop it 
early because of the emergence of unwanted effects.
Opinions about the potential value and drawbacks of psy-
chotropic drug treatment vary widely. A United States cross-
sectional study of patients with panic disorder attending primary 
care found high levels of willingness to see a psychiatrist or psy-
chotherapist, or to undergo pharmacological treatment [III] 
(Johnson et al., 2000). However a United Kingdom primary care 
qualitative study of patients’ views on anxiety and depression 
found marked preferences regarding their perceived health 
needs, and much scepticism about the value of pharmacological 
treatments [II] (Kadam et al., 2001). Certain patient groups may 
be particularly reticent about starting or continuing psychotropic 
drug treatment. For example, in a United States study of beliefs 
about psychotherapy and psychotropic drug treatment for an 
anxiety disorder which found few differences between diagnos-
tic groups, coexisting depression was associated with more 
favourable views regarding drug treatment, whereas individuals 
from black and minority ethnic groups were less favourably 
inclined towards pharmacological or psychological treatments 
[II] (Wagner et al., 2005).
Adherence to prescribed treatment may be enhanced by pro-
viding relevant information about treatment and minimising 
administrative challenges. A qualitative study of experiences of 
care among groups of treatment-adherent and non-adherent eco-
nomically disadvantaged patients with panic disorder found that 
providing information was empowering and reduced a sense of 
isolation; that patients used a continuing process to evaluate the 
benefits and risks of treatment; and that barriers to treatment 
were primarily logistical [II] (Craske et al., 2005). Another inves-
tigation of perceived barriers to care suggested that difficulties in 
the continuing treatment of panic disorder were primarily admin-
istrative, such as being uncertain where to seek help, worrying 
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about potential costs, a lack of health insurance cover, and a 
delay in receiving appointments [II] (Mukherjee et al., 2006).
Recommendations: ascertaining attitudes to care and 
treatment
● Explore attitudes and expectations about pharmaco-
logical and psychological treatment and correct any 
misconceptions with patients prior to making a specific 
treatment recommendation [S]
● Review patient attitudes and experiences periodically 
during the course of treatment [B]
● Consider the administrative aspects of practice organi-
sation to see whether these facilitate the care and treat-
ment of patients with anxiety disorders [S]
12. Pharmacological treatments in 
patients with anxiety disorders
It has often proved difficult to demonstrate the benefit of antide-
pressant drug treatment in patients with mild depressive symp-
toms and the same difficulty is likely to be seen in patients with 
milder forms of anxiety disorders. Randomised controlled trials 
across a range of anxiety disorders also often demonstrate a high 
placebo response [IV] (Baldwin et al., 2011b; Batelaan et al., 
2012; Blanco et al., 2013; Fineberg et al., 2013, 2012; Ipser and 
Stein, 2012) which suggests that non-specific effects of assess-
ment and monitoring can play a large part in overall improvement. 
It should be emphasised that treatment response is not immediate; 
that a transient worsening of symptoms can sometimes occur; that 
prolonged courses are needed to maintain an initial treatment 
response; and that psychotropic medications and psychological 
treatments can have additive effects in some disorders.
The selection of a particular drug class (and of a specific drug 
within that class) should be determined principally by the evi-
dence base supporting its use, and also by whether the patient has 
previous experience of treatment with that compound. The 
absence of a licensed indication does not necessarily mean an 
absence of evidence for the proposed treatment intervention: 
conversely it should not be assumed that all drugs within a class 
are likely to be efficacious in the treatment of a particular anxiety 
disorder, when one member of that class has proven efficacy [IV] 
(Aquilina et al., 2007; Baldwin and Kosky, 2007; Royal College 
of Psychiatrists, 2007). The presence of coexisting depressive 
symptoms of moderate or greater severity should guide treatment 
choice towards the prescription of antidepressant drugs rather 
than benzodiazepines.
12.1. SSRIs and SNRIs
SSRIs have ‘broad spectrum’ efficacy in both short-term and 
long-term treatment, and are generally well tolerated; and for 
these reasons are widely considered to be the first-line pharmaco-
logical approach in patients with anxiety disorders or obsessive-
compulsive disorder. However SSRIs have potentially 
troublesome adverse effects, including initial increased nervous-
ness, insomnia, nausea and sexual dysfunction [I (M)] (Gartlehner 
et al., 2011; Serretti and Chiesa, 2009; Sinclair et al., 2009). 
Fluoxetine and paroxetine are inhibitors of some cytochrome 
P450 enzymes and hence may interact with some other psycho-
tropic drugs and treatments for physical illness [IV] (Muscatello 
et al., 2012). When stopped abruptly, and even when tapered 
slowly, SSRIs can produce a discontinuation syndrome charac-
terised by dizziness, insomnia and flu-like symptoms [I (M)] 
(Baldwin et al., 2007; Schatzberg et al., 2006): this seems more likely 
with paroxetine and least likely with fluoxetine [II] (Tint et al., 2008).
The SNRIs duloxetine and venlafaxine have proven efficacy 
in short-term and long-term treatment of generalised anxiety dis-
order [IV] (Baldwin et al., 2011b), and placebo-controlled trials 
indicate that venlafaxine is also efficacious in the acute treatment 
and prevention of relapse in panic disorder [IV] (Batelaan et al., 
2012). Although the tolerability profiles of SSRIs and SNRIs in 
patients with anxiety disorders are not established fully, system-
atic reviews of studies in depressed patients suggest that duloxe-
tine and venlafaxine may be less well tolerated than the SSRIs [I 
(M)] (Cipriani et al., 2012; Schueler et al., 2011). Both duloxe-
tine and venlafaxine have been associated with discontinuation 
symptoms after abrupt withdrawal [I(M)] (Baldwin et al., 2007; 
Perahia et al., 2005) in adult patients, data being limited in chil-
dren and adolescents [IV] (Hosenbocus and Chahal, 2011). 
Although evidence is mixed (Harrison et al., 2004; Mbaya et al., 
2007; Thase, 1998) venlafaxine is sometimes associated with an 
increase in blood pressure, and monitoring is recommended with 
higher daily doses [IV] (Joint Formulary Committee, 2012). A 
systematic review [I (M)] (McIntyre et al., 2008) and the findings 
of pharmacoepidemiological studies [I (M)] (Strombom et al., 
2008; Wernicke et al., 2008a, 2008b) provide no consistent evi-
dence of an increased risk of hepatotoxicity with duloxetine, but 
it is recommended that duloxetine is avoided in patients with 
known liver disease and patients considered to be at risk of 
hepatic dysfunction [IV] (Joint Formulary Committee, 2012).
12.2. Other antidepressant drugs
Certain tricyclic antidepressants (TCAs) [IV] (Baldwin et al., 
2011b; Bandelow et al., 2008a; Batelaan et al., 2012; Blanco 
et al., 2013; Fineberg et al., 2012; Ipser and Stein, 2012) are effi-
cacious in some anxiety disorders, but TCAs are associated with 
a greater burden of adverse effects than either SSRIs or SNRIs 
[IV] (Anderson et al., 2008), and for this reason should be gener-
ally be reserved for use after a non-response to or poor tolerance 
of initial treatment with an SSRI or SNRI. TCAs should be 
avoided in patients considered to be at risk of suicide, due to their 
potential fatal toxicity after overdose [IV] (Thanacoody and 
Thomas, 2005; Woolf et al., 2007). As with some SSRIs, many 
possible pharmacokinetic interactions limit their use in patients 
taking concomitant medication (listed in Appendix 1 of the 
British National Formulary, Joint Formulary Committee, 2012). 
As with other antidepressants, stopping TCAs abruptly can cause 
a discontinuation syndrome [IV] (Schatzberg et al., 2006).
The traditional irreversible monoamine oxidase inhibitor 
(MAOI) phenelzine has proven efficacy in panic disorder and 
social phobia: but side effects and the need to follow dietary 
restrictions limit its use, so it should generally be reserved for 
when patients have not responded to, or proved intolerant of, 
other treatment approaches. Phenelzine overdose is potentially 
fatal [III] (White et al., 2008), and it should usually be avoided in 
patients considered to be at risk of suicide. Interactions involving 
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traditional MAOIs and serotonergic antidepressants such as 
SSRIs and clomipramine can be hazardous (Lane and Baldwin, 
1997). Moclobemide, a reversible inhibitor of mono-amine oxi-
dase A (RIMA) has proven efficacy in social phobia [IV] (Blanco 
et al., 2013) and some evidence of benefit in panic disorder [I 
(PCT)] (Ross et al., 2010): the reversibility of its action reduces 
the need for dietary restrictions at lower daily doses though 
avoidance of tyramine-containing foods is advisable at higher 
dosage [I (PCT)] (Dingemanse et al., 1998).
Agomelatine has proven efficacy in acute treatment (Stein 
et al., 2008a) and prevention of relapse (Stein et al., 2012) in 
generalised anxiety disorder: sexual dysfunction is less likely 
than with SSRI or SNRI antidepressants [I (M)] (Serretti and 
Chiesa, 2009), as are discontinuation symptoms [I (PCT)] 
(Goodwin et al., 2009; Montgomery et al., 2004): elevations of 
hepatic enzymes occur in more than 1% of treated patients and 
regular monitoring of liver function tests is required in the early 
months of treatment [IV] (McAllister-Williams et al., 2010). The 
evidence for the efficacy of mirtazapine in patients with anxiety 
disorders is limited and inconsistent (Andrisano et al., 2013; 
Muehlbacher et al., 2005; Schutters et al., 2010), but in depressed 
patients treatment-emergent sexual dysfunction is probably less 
frequent than with SSRIs [I (M)] (Watanabe et al., 2011).
12. 3. Benzodiazepines
Some benzodiazepines have proven efficacy in the treatment of 
patients with panic disorder, generalised anxiety disorder and 
social anxiety disorder [IV] (Baldwin et al., 2011b; Bandelow 
et al., 2008b; Batelaan et al., 2012; Blanco et al., 2013). However 
benzodiazepines can cause troublesome sedation and cognitive 
impairment in both short-term and long-term treatment, and tol-
erance and dependence can occur (especially in predisposed 
patients) with prolonged use: and it is hard to identify those 
patients at risk of developing long-term problems [IV] (Dell’Osso 
and Lader, 2012). It is uncertain whether benzodiazepines are 
efficacious in relieving depressive symptoms in patients with 
anxiety disorders but there is no evidence of efficacy for benzo-
diazepines in the acute treatment of patients with minor depres-
sion [I (M)] (Barbui et al., 2011) and antidepressants should 
therefore be preferred in patients with significant coexisting 
depressive symptoms. Benzodiazepines will usually be reserved 
for the further treatment of patients who have not responded to at 
least three previous treatments (such as after non-response to 
both an SSRI and an SNRI and a psychological intervention); but 
it has been argued that concerns about potential problems in 
long-term use should not prevent their use in patients with persis-
tent, severe, distressing, and impairing anxiety symptoms, when 
other treatments have proved ineffective [IV] (Baldwin and Talat, 
2012; Nutt, 2005).
12. 4. Pregabalin
Pregabalin has proven efficacy in both acute treatment and pre-
vention of relapse in generalised anxiety disorder [IV] (Baldwin 
et al., 2011b) and social anxiety disorder. In generalised anxiety 
disorder, it is efficacious in relieving depressive symptoms of 
mild to moderate intensity [I (M)] (Stein et al., 2008a), and in 
reducing the severity of sleep disturbance (Holsboer-Trachsler 
and Prieto, 2013). Common adverse effects include drowsiness 
and dizziness though it may be better tolerated than other medi-
cations in the acute treatment of generalised anxiety disorder [I 
(M)] (Baldwin et al., 2011a). Long-term treatment is accom-
panied by weight gain in approximately 20% of patients 
[III] (Montgomery et al., 2013). It is not subject to hepatic metab-
olism and is excreted unchanged in the urine, which is a potential 
advantage in patients with hepatic impairment and in patients 
taking other drugs metabolised by the liver, but potentially disad-
vantageous in patients with renal disease. There is no known 
untoward interaction with lithium. Spontaneous reports of 
adverse sexual side effects are uncommon but the incidence of 
treatment-emergent sexual dysfunction with pregabalin is uncer-
tain [IV] (Baldwin et al., 2013). Discontinuation symptoms after 
abrupt withdrawal of pregabalin have been reported, as has the 
abuse of pregabalin generally in individuals with a history of 
other substance abuse: but the relative potential for developing 
tolerance and abuse, when compared to with medications, is not 
established [IV] (Baldwin et al., 2013).
12. 5. Other agents
Antipsychotic drugs are often prescribed to patients with anxiety 
disorders, but the strongest evidence for benefit is restricted to 
acute treatment and prevention of relapse with quetiapine in gen-
eralised anxiety disorder [IV] (Baldwin et al., 2011b), and the 
augmentation of SSRI antidepressants in patients with obsessive-
compulsive disorder [IV] (Fineberg et al., 2012). The tolerability 
profile of antipsychotic drugs is such that they should generally 
be reserved for treatment after a non-response to other interven-
tions [IV] (National Institute for Health and Clinical Excellence, 
2011). The azapirone drug buspirone is efficacious in the acute 
treatment of generalised anxiety disorder [I (M)] (Chessick et al., 
2006), as is the anti-histamine drug hydroxyzine [I (M)] (Guaiana 
et al., 2010), though neither has published evidence of efficacy in 
the prevention of relapse.
Recommendations: general aspects of pharmacologi-
cal treatment
● Discuss the anticipated balance of potential benefits 
and potential risks of specific psychotropic medica-
tions with patients before starting treatment [S]
● Consider a SSRI for first-line treatment, as SSRIs are 
effective across the anxiety and related disorders, in 
both the short-term and long-term, and are generally 
well tolerated [A]
● Remain familiar with the evidence base for other 
classes of medication, as many patients do not respond 
to or are intolerant of SSRI treatment, but may respond 
to other classes of psychotropic drug [S]
● Discuss potential adverse effects early in treatment, 
including increased nervousness, worsened agitation, 
and review patient progress carefully over the first few 
weeks of treatment [A]
● Remember that benzodiazepines can be effective in 
many patients with anxiety disorders [A], but recog-
nise that their use should generally only be short-term:
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 and only considered beyond this in patients who have 
not responded to a succession of other treatment 
approaches [S]
● Discuss the potential for experiencing discontinuation 
or withdrawal symptoms during unforeseen abrupt 
interruptions to treatment and after the planned end of 
pharmacological treatment [S]
13. Psychological treatments in 
patients with anxiety disorders
Many patients with anxiety disorders or obsessive-compulsive 
disorder have a marked preference for psychological treatment 
approaches [II] (Patel and Simpson, 2010; Zoellner et al., 2009). 
Certain forms of psychotherapy, such as exposure therapy, cogni-
tive therapy and cognitive behavioural therapy (CBT), have 
largely consistent evidence of efficacy in the treatment of anxiety 
disorders [I (M)] (Hofmann and Smits, 2008). An early systematic 
review of counselling for primary care patients with emotional 
problems (including anxiety, depression, and ‘stress’) indicates 
that the short-term (but not long-term) efficacy of counselling was 
greater than that of standard general practitioner care, with or 
without antidepressant treatment [I (M)] (Bower et al., 2001): 
though a subsequent meta-analysis suggests that short-term coun-
selling is less beneficial than longer-term treatment with other 
psychological interventions [I (M)] (Cape et al., 2010). Some psy-
chological interventions – such as psychodynamic psychotherapy 
- have not been subject to extensive controlled investigations 
(Leichsenring, 2005; Lewis et al., 2008). Psychodynamic psycho-
therapy was reported to be superior to applied relaxation in 
patients with panic disorder (Leichsenring et al., 2009; Milrod 
et al., 2007), but has been found less beneficial than CBT in gen-
eralised anxiety disorder (Durham et al., 1999) . Many evaluations 
of the efficacy of psychological treatments have not employed an 
optimal psychological placebo control treatment: the use of wait-
ing list controls is inadequate to demonstrate potential efficacy.
The efficacy of psychological and pharmacological 
approaches is broadly similar in the acute treatment of anxiety 
disorders. In some studies, relapse rates are lower after an initial 
response to cognitive therapy with exposure than after response 
to drug treatment. For these reasons, patients should be offered a 
choice of treatment approaches, selection being affected by 
patient clinical features, needs and preference, and by the local 
availability of services able to offer evidence-based psychologi-
cal interventions [IV] (Haynes et al., 2002). In most anxiety dis-
orders (generalised anxiety disorder, social anxiety disorder, 
post-traumatic stress disorder, obsessive-compulsive disorder) it 
is uncertain whether combining psychological and pharmaco-
logical treatments is associated with greater long-term benefit 
than that which is seen with either treatment approach when 
given alone. However, previous concerns that prescription of 
psychotropic drugs might reduce the efficacy of psychological 
treatment are probably unfounded: in some anxiety disorders sys-
tematic reviews suggest that psychotropic drug administration 
can enhance the short-term efficacy of cognitive-behavioural 
interventions. As with pharmacological approaches, it should be 
emphasised that response to psychological treatment is not 
immediate; that transient worsening of symptoms can sometimes 
occur; that prolonged courses are often needed to maintain an 
initial treatment response; that dependence on the therapist may 
occur, with problems when treatment is stopped; and that encour-
aging short-term outcomes are no guarantee of good outcomes 
over the longer-term.
Given uncertainty about the value of combination treatment 
and widespread constraints in the availability of mental health ser-
vices, it may be best to plan sequential steps in patient manage-
ment [IV] (National Institute for Health and Clinical Excellence, 
2005, 2011). When psychological treatment is recommended, it 
should only be delivered by suitably trained and supervised staff, 
able to demonstrate that their clinical practice adheres to evidence-
based treatment protocols [IV] (National Institute for Health and 
Clinical Excellence, 2005). The potential effectiveness of initia-
tives designed to increase the uptake of psychological interven-
tions for patients with common mental health problems – such as 
the Improving Access to Psychological Therapies programme [IV] 
(Brown et al., 2010; Clark, 2011) in the United Kingdom – has not 
been established through formal randomised controlled trials.
A general range of 8–20 h of sessions of CBT may be needed 
in the treatment of anxiety disorders. In generalised anxiety dis-
order and panic disorder, a typical treatment course consists of 
approximately 16–20 h, up to half of which can be conducted by 
the patient in supervised ‘homework’ sessions, over a period of 
approximately four months [IV] (National Institute for Health 
and Clinical Excellence, 2011). In social anxiety disorder a 
standard course should consist of up to 14 sessions of 90 min 
duration over the course of four months [IV] (National Institute 
for Health and Care Excellence, 2013). In post-traumatic stress 
disorder, a standard course of psychological treatment might 
involve 8–12 sessions of trauma-focused CBT, delivered at 
weekly intervals [IV] (National Institute for Clinical Excellence 
(NICE), 2005). In obsessive-compulsive disorder, a typical initial 
treatment course might include approximately 16 h of interven-
tion based on exposure and response prevention, with longer and 
more intensive treatment in housebound patients [IV] (National 
Institute for Health and Clinical Excellence, 2005).
Recommendations: general aspects of psychological 
treatment
● Remember that the efficacy of psychological and phar-
macological approaches is broadly similar in the acute 
treatment of patients with anxiety disorders [A]
● Discuss the anticipated balance of potential benefits 
and potential risks of specific psychological interven-
tions with patients before starting treatment [S]
● Ensure that psychological treatments are only deliv-
ered by suitably trained and supervised staff, able to 
demonstrate that their clinical practice adheres to evi-
dence-based treatment protocols [A]
● Remind patients that response to psychological treatment 
is not immediate and that a prolonged course is usually 
needed to maintain an initial treatment response [S]
● Plan sequential steps in patient management rather 
than combining treatments from the start, as it is uncer-
tain whether combining is associated with greater long-
term benefit [D]
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14. The role of self-help and 
complementary approaches in anxiety 
disorders
Patient preference and the often sub-optimal effects of ‘standard’ 
pharmacological or psychological treatment approaches have 
encouraged the development of a range of self-help techniques 
and therapies in anxiety disorders; some undertaken as individu-
als, often through internet-based resources, and others in groups. 
Many patients and their carers derive considerable practical and 
emotional support from local self-help groups and national self-
help organisations (such as the United Kingdom organisations 
Anxiety-UK and Obsessive Action): though formal evaluations 
of the effectiveness of participation in such groups are sparse [I 
(M)] (Pistrang et al., 2008).
There have been relatively few randomised controlled trials 
of the efficacy and acceptability of self-help approaches under-
taken as individuals, and few studies have been conducted in 
diagnostically homogenous groups, with reliable outcome meas-
ures and robust statistical analysis. An early systematic review of 
six randomised controlled trials found evidence for the efficacy 
of self-help in primary care patients with mixed anxiety disor-
ders, greater efficacy being seen with more detailed instruction in 
use of self-help manuals [I (M)] (Van Boeijen et al., 2005). The 
findings of a systematic review of 21 studies in patients with 
depression or anxiety disorders suggest that guided self-help has 
similar effectiveness to face-to-face psychotherapy [I (M)] 
(Cuijpers et al., 2010): a subsequent systematic review of 31 ran-
domised controlled trials in anxiety disorders indicates that self-
help interventions are more effective than being placed on a 
waiting list, but less effective than therapist-administered treat-
ments [I (M)] (Lewis et al., 2012). In addition, the evidence base 
for self-help approaches in young people with anxiety disorders 
is limited [IV] (Parslow et al., 2008; Rickwood and Bradford, 
2012). In 2006, the UK National Institute for Clinical Excellence 
concluded that there was insufficient evidence to recommend the 
general introduction of computerised CBT for anxiety symptoms 
or disorders (National Institute for Health and Clinical Excellence, 
2006): however the findings of a systematic review of 26 studies 
in individuals with depression or anxiety disorders suggest that 
internet-based interventions offer promise, in overall manage-
ment [I (M)] (Griffiths et al., 2010); though there is a need to 
further investigate factors associated with beneficial outcomes 
(Andersson, 2012).
Many patients with anxiety disorders wonder whether tak-
ing herbal preparations or nutritional supplements might 
prove beneficial, either instead of or in conjunction with 
standard pharmacological or psychological treatments. 
Systematic reviews find some evidence for the potential effec-
tiveness of a number of ‘phytomedicines’, including Passiflora 
species extracts, Kava (Piper methysticum), and combinations 
of l-lysine and l-arginine (Lakhan and Vieira, 2010; Sarris 
et al., 2011b; Van der Watt et al., 2008). There is no current 
convincing evidence for the effectiveness of homoeopathic 
preparations in the treatment of patients with anxiety disor-
ders [I (M)] (Davidson et al., 2011; Pilkington et al., 2006). 
Kava preparations appeared to have some beneficial effects in 
patients with generalised anxiety disorder but have been with-
drawn in many countries due to potential hepatotoxic effects 
[IV] (Sarris et al., 2011a).
Other complementary approaches include regular exercise 
and interventions drawing on meditation techniques. A system-
atic review indicates that exercise training reduces anxiety symp-
toms in sedentary patients with long-term medical conditions [I 
(M)] (Herring et al., 2010); and regular walking may enhance the 
efficacy of group CBT, across a range of anxiety disorders [II] 
(Merom et al., 2008). In panic disorder, regular exercise is mar-
ginally superior to relaxation [I (PCT)] (Wedekind et al., 2010); 
but less effective than either the TCA clomipramine [I (PCT)] 
(Broocks et al., 1998) or group CBT [II] (Hovland et al., 2012). 
Preliminary evidence suggests that exercise training may be 
effective in obsessive-compulsive disorder (Abrantes et al., 
2009), generalised anxiety disorder (Herring et al., 2012) and 
social anxiety disorder (Jazaieri et al., 2012).
Meditation and yoga practices are often advocated, as part of 
the overall management of patients with anxiety disorders. Early 
systematic reviews found only minimal evidence for the effec-
tiveness of meditation therapy [I (M)] (Krisanaprakornit et al., 
2006) or mindfulness-based meditation [I (M)] (Toneatto and 
Nguyen, 2007). However another systematic review indicated 
that relaxation training (which often includes components of 
meditation) is effective in reducing anxiety symptoms in non-
clinical and clinical groups [I (M)] (Manzoni et al., 2008): and 
the findings of two recent systematic reviews suggest that medi-
tative therapies are effective in reducing anxiety symptoms 
(though their effect in anxiety disorders is uncertain) [I (M)] 
(Chen et al., 2012), and that mindfulness- and acceptance-based 
interventions are effective in reducing anxiety and co-existing 
depressive symptoms in patients with anxiety disorders [I (M)] 
(Vøllestad et al., 2012).
Recommendations: self-help and complementary 
approaches
● Remember that self-help approaches, such as use of 
internet-based educational resources, are potentially 
beneficial in patients with mild anxiety and depressive 
symptoms [A]
● Keep patients who use such resources under review as 
many will not improve, and so will need to undergo 
other forms of treatment [S]
● Enquire about the use by patients of herbal preparations 
or nutritional supplements, but remember that the evi-
dence base for their use is relatively slight, when com-
pared to the substantial evidence supporting the use of 
pharmacological and psychological interventions [S]
15. Costs of illness and cost-
effectiveness of treatment
Anxiety disorders are associated with a substantial economic bur-
den: both in health care systems (mainly direct costs of assessment, 
investigation, treatment and care), and in the wider society (includ-
ing premature mortality, unemployment, reduced productivity 
losses) [I] (Andlin-Sobcki and Wittchen, 2005; Gustavsson et al., 
2011; Wittchen et al., 2011). Using estimates to calculate the size 
of the population in the European Union that would be affected 
(69.1 million people), it was estimated that, in 2010, anxiety disor-
ders (excluding post-traumatic stress disorder) cost close to €66 
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billion [I] (Gustavsson et al., 2011). Treatment costs account for a 
small proportion of the overall costs of health care, and it has been 
argued that the increased costs of strategies to increase the recogni-
tion and evidence-based treatment in patients that would otherwise 
remain undetected and untreated would be small, compared to the 
saving arising from unemployment and reduced productivity at 
work [IV] (Baldwin et al., 2010; Issakidis et al., 2004). However 
there have been relatively few randomised controlled trials or sys-
tematic evaluations of the cost-effectiveness of pharmacological, 
psychological or self-help interventions across the broad range of 
anxiety disorders (Joesch et al., 2012; Konnopka et al., 2009; 
Lewis et al., 2012; Poirier-Bisson et al., 2010).
Investigations of the costs of illness and cost-effectiveness of 
individual anxiety disorders are limited. The cost-effectiveness 
of Improving Access to Psychological Therapies (IAPT) services 
within the UK is not established [III] (McCrone, 2013; Mukuria 
et al., 2013). For generalised anxiety disorder, cost-effectiveness 
studies provide evidence for the value of CBT, certain antide-
pressants, and pregabalin (Bereza et al., 2009; Heuzenroeder 
et al., 2004; Iskedjian et al., 2008; Jorgensen et al., 2006; Vera-
Llonch et al., 2010). Cost-effectiveness studies in panic disorder 
provide evidence for the value of CBT (Heuzenroeder et al., 
2004; Roberge et al., 2008) [II]; SSRI or tricyclic antidepressants 
(Heuzenroeder et al., 2004; McHugh et al., 2007); lifestyle 
approaches (Lambert et al., 2010) [III]; computerised interven-
tions (Klein et al., 2009; McCrone et al., 2009; Mihalopoulos 
et al., 2005) and early intervention (Smit et al., 2009). Brief inter-
ventions (Klein et al., 2009), monotherapies (McHugh et al., 
2007) and self-directed approaches (McCrone et al., 2009) may 
be more cost-effective than longer, combination treatment, or 
clinician-led approaches, respectively. Treatment studies in 
social anxiety disorder provide some evidence for the cost-effec-
tiveness of internet-delivered approaches [II] (Hedman et al., 
2011c; Titov et al., 2009), group CBT [II] (Hedman et al., 2011a), 
and for long-term treatment with the SSRI escitalopram in the 
prevention of relapse [I (PCT)] (Francois et al., 2008). The cost-
effectiveness of treatments for obsessive-compulsive disorder 
has been investigated only rarely, with limited evidence for the 
greater cost-effectiveness of ‘stepped care’ compared to standard 
CBT [II] (Tolin et al., 2011) and group CBT in children and ado-
lescents [III] (Farrell et al., 2012). In post-traumatic stress disor-
der, there is only modelled or limited evidence, for the 
cost-effectiveness of trauma-focused CBT in the treatment of 
sexually abused children, which may be enhanced when com-
bined with an SSRI [III] (Gospodarevskaya and Segal, 2012); 
and for virtual reality graded exposure therapy in combat-related 
trauma [III] (Wood et al., 2009).
16. Management of generalised 
anxiety disorder
16. 1. Recognition and diagnosis
Generalised anxiety disorder is amongst the most common of 
mental disorders in primary medical care, and is associated with 
increased use of health services. However it is often not recog-
nised, possibly because only a minority of patients present 
with anxiety symptoms (most present with physical symp-
toms), and doctors tend to overlook anxiety unless it is a pre-
senting complaint [I] (Munk-Jorgensen et al., 2006). The 
degree of functional impairment associated with generalised 
anxiety disorder is similar to that with major depression [I] 
(Wittchen et al., 2000). Patients with ‘co-morbid’ depression and 
generalised anxiety disorder have a more severe and prolonged 
course of illness and greater functional impairment (Tyrer et al., 
2004). Patients with co-morbid depression are more likely to be 
recognised as having a mental health problem, though not neces-
sarily as having generalised anxiety disorder [I] (Weiller et al., 
1998; Wittchen et al., 2002).
16.2. Acute treatment
The findings of systematic reviews [I (M)] (Baldwin et al., 
2011b; National Institute for Health and Clinical Excellence, 
2011) and randomised placebo-controlled trials of acute treat-
ment of patients with generalised anxiety disorder together pro-
vide substantial evidence for the efficacy of many antidepressant 
drugs – including SSRIs (citalopram, escitalopram, paroxetine, 
sertraline), SNRIs (duloxetine, venlafaxine), the tricyclics imi-
pramine and opipramol, trazodone, and agomelatine [IV] 
(Baldwin et al., 2011a). Other compounds with efficacy in pla-
cebo-controlled acute treatment studies include pregabalin [I 
(M)] (Wensel et al., 2012), some benzodiazepines (alprazolam, 
diazepam, lorazepam) [I (M)] (Martin et al., 2007), buspirone [I 
(M)] (Chessick et al., 2006), some antipsychotic drugs (quetia-
pine, trifluoperazine) [I (M)] (Lalonde and Van Lieshout, 2011) 
and the antihistamine hydroxyzine [I (M)] (Guaiana et al., 2010). 
Beta-blockers are often used in primary medical management of 
physical symptoms of anxiety but placebo-controlled evidence of 
efficacy in acute treatment of patients with generalised anxiety 
disorder is minimal [I (PCT)] (Meibach et al., 1987).
There have been relatively few randomised comparator-
controlled studies of acute treatment in generalised anxiety 
disorder [I (M)] (Baldwin et al., 2011b; National Institute for 
Health and Clinical Excellence, 2011) and most reveal no sig-
nificant differences in overall efficacy between active com-
pounds. An early analysis of randomised controlled trials of 
acute treatment found an overall mean effect size of 0.39: 
medications with higher effect sizes were pregabalin, hydrox-
yzine and SNRIs; and with lower effect sizes were benzodiaz-
epines, SSRIs and buspirone [I (M)] (Hidalgo et al., 2007). The 
tentative findings of a mixed treatment comparison suggest 
fluoxetine, sertraline and pregabalin have some advantages 
over other medications: among currently licensed treatments in 
the United Kingdom, duloxetine, escitalopram and pregabalin 
may have some advantages over paroxetine and venlafaxine [I 
(M)] (Baldwin et al., 2011b). It is uncertain whether antide-
pressant drugs, pregabalin and benzodiazepines differ in their 
relative efficacy in reducing the severity of psychological or 
somatic anxiety symptoms [IV] (Baldwin et al., 2011a). The 
findings of fixed-dose randomised placebo-controlled trials 
provide some evidence of a dose-response relationship for pre-
gabalin [I (M)] (Bech, 2007; Lydiard et al., 2010), but studies 
with antidepressant drugs provide no consistent evidence for a 
dose-relationship [IV] (Baldwin et al., 2011a). Although not an 
antidepressant, a post hoc pooled analysis of randomised pla-
cebo-controlled trials with pregabalin indicate that it is effica-
cious in reducing depressive symptom severity in patients with 
mild to moderate intensity of depressive symptoms [I (M)] 
(Stein et al., 2008b).
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16.3. Longer term treatment
The findings of acute treatment studies indicate that the proportion 
of responding patients steadily increases over time [IV] (Baldwin 
et al., 2011a). Continuing with SSRI or SNRI treatment is associ-
ated with an increase in overall response rates: from 8–24 weeks 
with escitalopram or paroxetine [II] (Bielski et al., 2005); from 
4–12 weeks with sertraline [I (PCT)] (Allgulander et al., 2004a) 
and from 8–24 weeks with venlafaxine [I (PCT)] (Montgomery 
et al., 2002). However, the findings of post hoc analyses of data 
from randomised double-blind placebo-controlled studies with 
duloxetine [I (M)] (Pollack et al., 2008), escitalopram [I (M) 
(Baldwin et al., 2009), and with alprazolam, pregabalin and venla-
faxine [I (M) (Baldwin et al., 2011a) all suggest that response is 
likely only if there is an onset of effect within four weeks of treat-
ment. The findings of randomised placebo-controlled relapse-
prevention studies in patients who have responded to previous 
‘open’ acute treatment of varying lengths reveal a significant 
advantage for staying on active medication (agomelatine, duloxe-
tine, escitalopram, paroxetine, pregabalin, quetiapine, venlafaxine, 
vortioxetine), when compared with switching to placebo, for peri-
ods of between 6–18 months (Baldwin et al., 2011b, 2012; 
Katzman et al., 2011; Rickels et al., 2010).
16.4. Comparative efficacy of psychological, 
pharmacological, and combination 
treatments
Pharmacological or psychological treatments, when delivered sin-
gly, have broadly similar efficacy in acute treatment [I (M)] 
(Bandelow et al., 2007a; National Institute for Health and Clinical 
Excellence, 2011). The efficacy of CBT and applied relaxation 
appears superior to that of other psychological interventions 
(National Institute for Health and Clinical Excellence, 2011). A 
randomised controlled trial found that augmentation of venlafax-
ine with CBT conferred no additional benefit, when compared 
with venlafaxine alone [II] (Crits-Christoph et al., 2011) but it is 
uncertain whether combining drug and psychological treatments 
is associated with greater overall efficacy than is seen with either 
treatment, when given alone [I (M)] (Bandelow et al., 2007a), and 
a ‘stepped care’ approach is recommended [IV] (National Institute 
for Health and Clinical Excellence, 2011). Anxiety symptom 
severity at follow-up after initial treatment is lower with CBT than 
with other forms of psychological treatment [III] (Durham et al., 
2005): but the comparative efficacy of pharmacological and psy-
chological approaches over the long-term is not established.
16. 5. Further management after non-
response to initial treatment
Many patients do not respond to first-line pharmacological or 
psychological interventions. There is only inconsistent evidence 
for a dose-response relationship with antidepressant drugs, but 
some patients who have not responded to an initial low dosage 
may respond to a higher daily dose. The efficacy of pregabalin 
when compared with placebo is more marked at higher daily 
doses (200 mg or higher) [I (M)] (Bech, 2007; Lydiard et al., 
2010). Switching between pharmacological and psychological 
treatments with proven efficacy may be helpful [IV] (National 
Institute for Health and Clinical Excellence, 2011).
The addition of pregabalin to SSRI or SNRI antidepressant 
drugs is superior to continued treatment with antidepressants alone 
[I (PCT)] (Rickels et al., 2012). The findings of small randomised 
placebo-controlled augmentation studies suggest that augmenta-
tion of antidepressants with antipsychotic drugs (olanzapine, que-
tiapine, risperidone) may be beneficial [I (PCT)] (Brawman-Mintzer 
et al., 2005; Pollack et al., 2006; Altamura et al., 2011), but the 
evidence for quetiapine augmentation is inconsistent [I (PCT)] 
(Khan et al., 2011; Simon et al., 2008), and uncertain for ziprasi-
done augmentation [I (PCT)] (Lohoff et al., 2010).
Alternative treatments which have been found helpful in 
some patients include multi-faith spiritually based intervention 
[II] (Koszycki et al., 2010); Galphimia glauca (‘thyrallis’) [I 
(PCT)] (Herrera-Arellano et al., 2007), Matricaria recutita 
extract (chamomile) [I (PCT)] (Amsterdam et al., 2009), ‘Silexa’ 
lavender oil preparation [I (PCT)] (Woelk and Schlaefke, 2010), 
‘relaxing room therapy’ [III] (Sherman et al., 2010), yoga-based 
breathing programme [III] (Katzman et al., 2012) and ‘balneo-
therapy’ (hydrotherapy with message) [III] (Dubois et al., 2010): 
but more investigation of these approaches is needed before they 
can be recommended.
Recommendations: managing patients with general-
ised anxiety disorder
Detection and diagnosis
● Become familiar with the symptoms and signs of gen-
eralised anxiety disorder [S]
● Ask about the presence of coexisting depressive symp-
toms [A]
● Ask about long-standing anxiety in patients with 
depressive or unexplained physical symptoms [S]
● Assess any comorbid physical illness and enquire 
about excess alcohol consumption [S]
Acute treatment
● Choose an evidence-based acute treatment [A]
○ pharmacological: most SSRIs (citalopram, escitalo-
pram, paroxetine, sertraline), duloxetine, venlafaxine, 
pregabalin, agomelatine, quetiapine, some benzodi-
azepines (alprazolam, diazepam, lorazepam), imipra-
mine, buspirone, hydroxyzine and trazodone [A]
○ psychological: cognitive-behaviour therapy, 
applied relaxation [A]
● Take account of patient clinical features, needs and 
preference and local service availability when choos-
ing treatment, as pharmacological and psychological 
approaches have broadly similar efficacy in acute treat-
ment [S]
● Consider an SSRI for first-line pharmacological treat-
ment [A]
● SNRIs and pregabalin may be considered as alternative 
initial treatments if SSRIs are judged to be unsuitable [A]
● Remember that higher daily doses of pregabalin may 
be associated with greater response rates [A]
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● Advise the patient that treatment periods of up to 12 weeks 
may be needed to assess efficacy [S] but recognise that an 
absence of clinical benefit within four weeks warns that a 
response to unchanged treatment is unlikely [A]
Longer-term treatment
● Continue drug treatment for up to 18 more months in 
patients who have responded to treatment [A]
● Use a treatment approach that is known to be effica-
cious in preventing relapse [S]
● Recommend CBT over other forms of psychological 
treatment as it may reduce relapse rates better than 
other psychological treatments [C]
● Monitor effectiveness and acceptability regularly over 
the course of treatment [S]
● When stopping treatment, reduce the dose gradually 
over an extended period to avoid discontinuation and 
rebound symptoms [A]: in the absence of evidence a 
minimum of three months is recommended for this 
taper period [D]
Combination of drugs and psychological treatment
● Routinely combining drug and psychological approaches 
is not recommended for initial treatment [A]
When initial treatments fail
● Consider raising the dosage of pregabalin if the current 
dosage is well tolerated [A]
● Consider switching to another evidence-based treatment 
[D]
● Consider combining evidence-based treatments only 
when there are no contraindications [S]
● Consider pregabalin augmentation after a non-response 
to initial SSRI or SNRI treatment [A]
● Consider use of benzodiazepines after a non-response 
to SSRI, SNRI, pregabalin and buspirone treatment [S]
● Consider combining drug treatment and cognitive-
behaviour therapy [D]
● Consider referral to regional or national specialist ser-
vices in treatment refractory patients [S]
17. Management of panic disorder
17.1. Recognition and diagnosis
Accurate diagnosis of panic disorder is dependent upon estab-
lishing the presence of recurring panic attacks (i.e. short-lived 
periods of severe psychological and physical symptoms of anxi-
ety, typically peaking within 10 min and resolving within 30 
min), at least some of which are, or have been, unexpected. There 
should be intervening periods of comparative freedom from anxi-
ety between attacks; but the presence of associated concern, 
worry or change in behaviour due to an anticipated risk of having 
further panic attacks [IV] (Roy-Byrne et al., 2006). There is sub-
stantial overlap between panic disorder and agoraphobia, in com-
munity and clinical samples [I] (Goodwin et al., 2005; Wittchen 
et al., 2010). Patients with panic disorder are often not recognised 
or accurately diagnosed in primary [IV] (National Collaborating 
Centre for Mental Health, 2011) or secondary medical care [I] 
(Burton et al., 2011; Deacon et al., 2008), despite their consider-
able use of emergency, cardiac, gastrointestinal, neurological and 
mental health services [IV] (Roy-Byrne et al., 2006). There is 
considerable co-morbidity with other mental disorders, including 
anxiety disorders, bipolar disorder and major depression [IV] 
(Roy-Byrne et al., 2006): co-morbid panic and depression is par-
ticularly common, and associated with greater disability and 
impairment, and increased use of health services [I] (Roy-Byrne 
et al., 2000).
17.2. Acute treatment
Systematic reviews demonstrate that a range of pharmacological 
[IV] (Andrisano et al., 2013, Batelaan et al., 2012;), psychological 
[IV] (Schmidt and Keough, 2010) and combination [I (M)] 
(Furukawa et al., 2007; Watanabe et al., 2007) interventions are 
effective in the acute treatment of patients with panic disorder. 
Little is known about the efficacy of pharmacological or psycho-
logical treatment in patients with agoraphobia but without panic 
attacks (Perna et al., 2011). The findings of randomised double-
blind placebo-controlled trials of antidepressants indicate that all 
SSRIs (escitalopram, citalopram, fluoxetine, fluvoxamine, parox-
etine, sertraline); the SNRI venlafaxine; the selective noradrena-
line reuptake inhibitor reboxetine; some TCAs (clomipramine, 
desipramine, imipramine, lofepramine); the MAOI phenelzine; 
some benzodiazepines (alprazolam, clonazepam, diazepam, loraz-
epam); and some anticonvulsants (gabapentin, sodium valproate) 
are all efficacious in acute treatment [IV] (Batelaan et al., 2012).
The findings of randomised comparator-controlled studies 
provide some evidence for beneficial effects with mirtazapine 
[II] (Ribeiro et al., 2001) and moclobemide [II] (Kruger and 
Dahl, 1999; Tiller et al., 1999). The relative efficacy and tolera-
bility of differing pharmacological treatments is uncertain, but 
there may be efficacy advantages for venlafaxine, and tolerability 
disadvantages for fluvoxamine and reboxetine [I (M)] (Andrisano 
et al., 2013). A post hoc analysis of findings from a randomised 
placebo-controlled trial suggests that escitalopram is superior to 
citalopram [I (PCT)] (Bandelow et al., 2007b); and randomised 
controlled trials suggest that some SSRIs (fluvoxamine, paroxe-
tine) are more effective than some noradrenaline reuptake inhibi-
tors (maprotiline, reboxetine) [II] (Bertani et al., 2004; Den Boer 
and Westenberg, 1988). Medications with a lack of efficacy in the 
acute treatment of patients with panic disorder include the antide-
pressant bupropion [I (PCT)] (Sheehan et al., 1983), the beta-
blocker propranolol [I (PCT)] (Munjack et al., 1989); and 
buspirone[I (PCT)] (Sheehan et al., 1988). The potential value of 
antipsychotic drug monotherapy in acute treatment is unknown [I 
(M)] (Depping et al., 2010).
17.3. Longer term treatment
The findings of acute treatment studies indicate that the propor-
tion of responding patients steadily increases over time [IV] 
(Batelaan et al., 2012). Double-blind studies indicate that con-
tinuing SSRI or clomipramine treatment from 12–52 weeks is 
associated with an increase in overall treatment response rates [I 
(PCT)] (Ballenger, 1998; Lecrubier and Judge, 1997; Lepola 
et al., 1998). The relative effectiveness and acceptability of 
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differing medications over long-term treatment is uncertain, but a 
12-month comparison of the efficacy and tolerability of differing 
SSRIs (citalopram, fluoxetine, fluvoxamine, paroxetine) sug-
gests that fluvoxamine is less likely to be associated with weight 
gain or sexual adverse effects [III] (Dannon et al., 2007); and the 
findings of a randomised naturalistic parallel-group study of 34 
months of continuation treatment with clonazepam or paroxetine 
suggest that clonazepam is marginally more effective and better 
tolerated [II] (Nardi et al., 2012).
Placebo-controlled and other relapse-prevention studies in 
patients who have responded to previous acute treatment reveal a 
significant advantage for staying on active medication (fluoxe-
tine, imipramine, paroxetine, sertraline, venlafaxine), compared 
to switching to placebo, for periods of up to six months: but the 
optimal duration of continuation treatment is uncertain [I (M)] 
(Donovan et al., 2010).
17.4. Comparative efficacy of psychological, 
pharmacological, and combination 
treatments
The findings of pooled analyses and randomised controlled trials 
together indicate that pharmacological and psychological treat-
ments, when delivered singly, have broadly similar efficacy in 
acute treatment [I (M)] (Bandelow et al., 2007b; McHugh et al., 
2009). In acute treatment, the combination of psychotherapy with 
antidepressants is superior to psychotherapy or an antidepressant, 
when either is given alone (Furukawa et al., 2007; Koszycki 
et al., 2011; Van Apeldoorn et al., 2010): the advantage over 
monotherapies persists as long as the antidepressant is continued, 
but combination treatment is more effective than antidepressant 
treatment alone, though no different to psychological treatment 
alone, in preventing relapse [I (M)] (Furukawa et al., 2007). 
Based on limited data, the combination of psychotherapy with a 
benzodiazepine is probably superior to a benzodiazepine when 
given alone during acute treatment, but the relative efficacy of 
combination treatment and monotherapies in the prevention of 
relapse is uncertain [I (M)] (Watanabe et al., 2007). However 
combination treatment appears no more cost-effective than anti-
depressant or CBT monotherapy [II] (McHugh et al., 2007). 
Exploratory placebo-controlled studies suggest that the addition 
of d-cycloserine may hasten the onset of effect [I (PCT)] 
(Siegmund et al., 2011) or increase overall effectiveness [I 
(PCT)] (Otto et al., 2010) of CBT in the acute treatment of 
patients with panic disorder.
17. 5. Further management after non-
response to initial treatment
Many patients do not respond to first-line pharmacological or 
psychological interventions. The findings of randomised fixed-
dose placebo-controlled studies suggest that higher daily doses of 
some antidepressants [I (PCT)] (paroxetine, fluoxetine: Ballenger 
et al., 1998; Michelson et al., 1998) but not others [I (PCT)] (cit-
alopram, venlafaxine: Pollack et al., 2007; Wade et al., 1997) 
may be superior in efficacy to lower doses. However, the evi-
dence to support dose escalation after an initial lack of response 
to lower doses is only limited [I (PCT)] (Michelson et al., 2001) 
or negative [I (PCT)] (Simon et al., 2009).
Switching between pharmacological and psychological treat-
ments with proven efficacy may be helpful [IV] (National Institute 
for Health and Clinical Excellence, 2011). A single-blind crosso-
ver study in non-responders suggests that switching between cit-
alopram and reboxetine may be worthwhile [II] (Seedat et al., 
2003). A randomised placebo-controlled study found that pindolol 
augmentation of fluoxetine was superior to continued fluoxetine 
alone [I (PCT)] (Hirschmann et al., 2000). A small open study 
involving the addition of fluoxetine in patients taking a TCA, or 
vice versa, found some evidence of benefit [III] (Tiffon et al., 
1994). Combined treatment with sodium valproate and clonaze-
pam may be beneficial in patients who have not responded to sev-
eral previous medications [III] (Ontiveros and Fontaine, 1992); as 
has the addition of olanzapine to other medications [III] (Sepede 
et al., 2006). Addition of lithium to clomipramine was found suc-
cessful in a single case report [III] (Cournoyer, 1986).
Augmentation of CBT with paroxetine may be superior to 
continuing with CBT alone, in patients who did not previously 
respond over 15 sessions [I (PCT)] (Kampman et al., 2002); and 
addition of group CBT may be beneficial in non-responders to 
pharmacological approaches [III] (Heldt et al., 2003; Otto et al., 
1999; Pollack et al., 1994). However a small study in multiply 
treatment-resistant patients found no difference in effectiveness 
between the augmentation of medication with CBT or ‘medica-
tion optimisation’ (SSRI plus clonazepam) [I (PCT)] (Simon 
et al., 2009).
Recommendations: managing patients with panic 
disorder
Detection and diagnosis
● Become familiar with the symptoms and signs of panic 
attacks and panic disorder [S]
● Ask about the presence of coexisting depressive symp-
toms [A]
● Assess the level of agoraphobic avoidance to help 
judge the severity of the condition [S]
● Ask about panic attacks and agoraphobia in patients 
with medically unexplained physical symptoms [D]
Acute treatment
● Choose an evidence-based acute treatment [A]
○ pharmacological: all SSRIs, some TCAs (clomi-
pramine, desipramine, imipramine, lofepramine) 
venlafaxine, reboxetine, some benzodiazepines 
(alprazolam, clonazepam, diazepam, lorazepam), 
some anticonvulsants (gabapentin, sodium val-
proate) [A]
○ psychological: cognitive-behaviour therapy [A]
● Avoid prescribing propranolol, buspirone and bupro-
pion [A]
● Take account of patient clinical features, needs and 
preference and local service availability when choos-
ing treatment, as pharmacological and psychological 
approaches have broadly similar efficacy in acute treat-
ment [S]
● Consider an SSRI for first-line pharmacological treat-
ment [S]
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● Consider increasing the dose if there is insufficient 
response, but remember that the evidence for a dose-
response relationship with SSRIs and venlafaxine is 
inconsistent [A]
● Initial side effects can be minimised by slowly increasing 
the dose or by adding a benzodiazepine for a few weeks 
[D]
● Advise the patient that treatment periods of up to 12 
weeks may be needed to assess efficacy [A]
Longer-term treatment
● Continue drug treatment for at least six months in 
patients who have responded to treatment [A]
● Use an approach that is known to be efficacious in pre-
venting relapse [S]
● Monitor effectiveness and acceptability regularly over 
the course of treatment [S]
● When stopping treatment, reduce the dose gradually over 
an extended period to avoid discontinuation and rebound 
symptoms [A]: in the absence of evidence a minimum of 
three months is recommended for this taper period [D]
Combination of drugs and psychological treatment
● Consider combining cognitive therapy with antidepres-
sants as this has greater efficacy and may reduce 
relapse rates better than drug treatment alone [A]
● Consider combining cognitive therapy with benzodiaz-
epines (being mindful of potential long-term problems) 
as this probably has greater efficacy than drug treat-
ment alone [A]
When initial treatments fail
● Consider raising the dosage if the current dosage is 
well tolerated [A]
● Consider switching to another evidence-based treat-
ment [D]
● Consider combining evidence-based treatments only 
when there are no contraindications [S]
● Consider combining evidence-based pharmacological 
and psychological treatments [A]
● Consider referral to regional or national specialist ser-
vices in treatment refractory patients [S]
18. Management of specific phobia 
(also known as simple or isolated 
phobia)
18.1. Recognition and diagnosis
Specific fears of objects, animals, people or situations are wide-
spread in children, adolescents and adults, but only a minority of 
affected individuals reach the full diagnostic criteria for specific 
phobia. Specific (or simple or isolated) phobia has an estimated 
12-month prevalence of 6.4% [I] (Wittchen et al., 2011), and had 
a lifetime prevalence of 9.4% in the United States National 
Epidemiologic Survey on Alcohol and Related Conditions [I] 
(Stinson et al., 2007). Many affected individuals have multiple 
fears, whose presence is associated with an earlier onset, greater 
severity and impairment, and more frequent psychiatric comor-
bidity [I] (Burstein et al., 2012; Stinson et al., 2007). Most indi-
viduals with specific phobia do not present for treatment of that 
condition, presentation being more likely with comorbid anxiety 
or mood disorders [I] (Mackenzie et al., 2012).
18.1 Treatment
The effectiveness and acceptability of psychological or pharma-
cological treatments for specific phobia has been relatively 
under-researched when compared to other anxiety disorders. The 
findings of a meta-analytic review of 33 randomised controlled 
treatment studies indicate that exposure-based therapies (particu-
larly those involving in vivo exposure) are more effective than 
other psychological interventions: effectiveness being seen 
regardless of the nature of the specific phobia, and being some-
what greater with multiple rather than single sessions [I (M)] 
(Wolitzky-Taylor et al., 2008).
Most patients respond to psychological approaches, but some 
may benefit from pharmacological treatment. The findings of 
small randomised placebo-controlled trials provide evidence for 
the efficacy of escitalopram [I (PCT)] (Alamy et al., 2008) and 
paroxetine [I (PCT)] (Benjamin et al., 2000). The findings of 
small randomised placebo-controlled studies suggest that the 
efficacy of exposure therapy can be enhanced through prior 
administration of d-cycloserine [I (PCT)] (Nave et al., 2012; 
Ressler et al., 2004): but not all evidence is consistent [I (PCT)] 
(Guastella et al., 2007), and its administration after a session is 
not associated with enhanced efficacy [I (PCT)] (Tart et al., 
2013). Prior administration of naltrexone may reduce the effec-
tiveness of exposure therapy [I (PCT)] (Kozak et al., 2007). It is 
unclear whether concomitant use of benzodiazepines enhances or 
reduces the efficacy of behavioural approaches.
Recommendations: managing patients with specific (or 
simple) phobia
● Become familiar with the symptoms and signs of spe-
cific phobia [S]
● Assess the number of fears, the level of anxiety, and the 
degree of impairment to judge severity [A]
● Ask about symptoms of comorbid disorders in treat-
ment-seeking patients [A]
● Use psychological treatments based on exposure tech-
niques as first-line treatment [A]
● Consider SSRI treatment for patients who have not 
responded to psychological interventions [A]
19. Management of social anxiety 
disorder (also known as social 
phobia)
19.1. Recognition and diagnosis
Social anxiety disorder is often not recognised in primary medi-
cal care [I] (Weiller et al., 1996) but detection can be enhanced 
through the use of screening questionnaires in psychologically 
distressed primary care patients [I] (Donker et al., 2010; Terluin 
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et al., 2009). Social anxiety disorder is often misconstrued as 
mere ‘shyness’ but can be distinguished from shyness by the 
higher levels of personal distress, more severe symptoms and 
greater impairment [I] (Burstein et al., 2011; Heiser et al., 
2009). The generalised sub-type (where anxiety is associated 
with many situations) is associated with greater disability and 
higher comorbidity, but patients with the non-generalised sub-
type (where anxiety is focused on a limited number of situa-
tions) can be substantially impaired [I] (Aderka et al., 2012; 
Wong et al., 2012). Social anxiety disorder is hard to distin-
guish from avoidant personality disorder, which may represent 
a more severe form of the same condition [IV] (Reich, 2009). 
Patients with social anxiety disorder often present with symp-
toms arising from comorbid conditions (especially depression), 
rather than with anxiety symptoms and avoidance of social and 
performance situations [I] (Stein et al., 1999). There are strong, 
and possibly two-way, associations between social anxiety dis-
order and dependence on alcohol and cannabis [I] (Buckner 
et al., 2008; Robinson et al., 2011).
19.2. Acute treatment
The findings of meta-analyses and randomised placebo- 
controlled treatment studies indicate that a range of approaches 
are efficacious in acute treatment [IV] (Blanco et al., 2013). CBT 
is efficacious in adults [I (M)] (Hofmann and Smits, 2008) and 
children [I (M)] (James et al., 2005): cognitive therapy appears 
superior to exposure therapy [I (M)] (Ougrin, 2011), but the evi-
dence for the efficacy of social skills training is less strong [IV] 
(Ponniah and Hollon, 2008).
Antidepressant drugs with proven efficacy include most 
SSRIs (escitalopram, fluoxetine, fluvoxamine, paroxetine, sertra-
line), the SNRI venlafaxine, the MAOI phenelzine, and the 
RIMA moclobemide: nefazodone is not efficacious and the evi-
dence for mirtazapine is inconsistent [I (M)] (De Menezes et al., 
2011). The potential efficacy of tricyclic antidepressants is 
unknown. Some benzodiazepines (bromazepam and clonazepam, 
but not alprazolam) and anticonvulsants (gabapentin and prega-
balin, but not levatiracetam), and the antipsychotic olanzapine 
also appear efficacious in acute treatment [IV] (Blanco et al., 
2013). Neither the 5-hydroxytryptamine (5-HT1A) partial agonist 
buspirone, nor the beta-blocker atenolol are efficacious in gener-
alised social anxiety disorder [IV] (Blanco et al., 2013), although 
a number of small single-dose placebo-controlled cross-over 
studies together suggest that beta-blockers can be beneficial in 
reducing anxiety symptoms in individuals with ‘performance 
anxiety’ (for example, when speaking in public), which overlaps 
with mild non-generalised social anxiety disorder) [IV] (Blanco 
et al., 2013). 
There have been relatively few randomised comparator-con-
trolled studies of acute treatment and most reveal no significant 
differences in overall efficacy or tolerability between active com-
pounds. In randomised placebo- and comparator- controlled stud-
ies, phenelzine was superior to placebo, but atenolol was not [I 
(PCT)] (Liebowitz et al., 1992); phenelzine was superior to pla-
cebo, but alprazolam was not [I (PCT)] (Gelernter et al., 1991); 
and escitalopram was found superior to paroxetine [I (PCT)] 
(Lader et al., 2004); venlafaxine and paroxetine had similar over-
all efficacy in two placebo-controlled studies [I (PCT)] 
(Allgulander et al., 2004b; Liebowitz et al., 2005).
19.3. Longer term treatment
The findings of acute treatment studies indicate that the propor-
tion of responding patients increases steadily over time [IV] 
(Blanco et al., 2013). Double-blind studies indicate that continu-
ing SSRI or SNRI treatment from 12–24 weeks is associated with 
an increase in overall treatment response rates [I (M)] (Lader 
et al., 2004; Stein et al., 2002a, 2003). A post hoc analysis of the 
clinical trial database for escitalopram indicates that response is 
unlikely if there is no onset of clinical effect within the first four 
weeks of treatment [I (PCT)] (Baldwin et al., 2009): however a 
post hoc analysis of the clinical trial database with paroxetine 
indicates that many non-responders to treatment at eight weeks 
become responders with a further four weeks of double-blind 
treatment [I (PCT)] (Stein et al., 2002a). The findings of ran-
domised placebo-controlled relapse-prevention studies in 
patients who have responded to previous acute treatment reveal a 
significant advantage for staying on active medication (clonaze-
pam, escitalopram, paroxetine, pregabalin, sertraline) for up to 
six months [IV] (Blanco et al., 2013).
19.4. Comparative efficacy of 
pharmacological, psychological and 
combination treatments
Pharmacological and psychological treatments, when delivered 
singly, have broadly similar efficacy in acute treatment [I (M)] 
(Canton et al., 2012). However, acute treatment with cognitive 
therapy (group or individual) is associated with a reduced risk of 
symptomatic relapse at follow-up [I (M)] (Canton et al., 2012). It 
is unlikely that the combination of pharmacological with psycho-
logical treatments is associated with greater overall efficacy than 
with either treatment, when given alone, as only one in four stud-
ies of the relative efficacy of combination treatment found evi-
dence for superior efficacy [I (PCT)] (Blanco et al., 2010). The 
findings of small randomised placebo-controlled studies suggest 
that the efficacy of psychological treatment may be enhanced 
through prior administration of d-cycloserine [I (PCT)] (Guastella 
et al., 2008; Hofmann et al., 2006) or cannabidiol [I (PCT)] 
(Bergamaschi et al., 2011).
19.5. Further management after non-
response to initial treatment
The findings of fixed-dose randomised controlled trials do not 
provide consistent evidence of a dose-response relationship 
with antidepressant drugs: but a fixed-dose study of pregabalin 
found that only the higher daily dosage was efficacious [I 
(PCT)] (Pande et al., 2004). A double-blind randomised con-
trolled dosage escalation trial found no advantage for increas-
ing to a higher daily dosage (120 mg) of duloxetine, when 
compared to continuing treatment with a lower (60 mg) dosage 
[II] (Simon et al., 2010). Switching between treatments with 
proven efficacy may be helpful [IV] (Blanco et al., 2013). An 
uncontrolled study of augmentation of SSRI treatment with 
buspirone found some evidence of beneficial effects [III] (Van 
Ameringen et al., 1996); but a placebo-controlled crossover-
study of the augmentation of paroxetine with pindolol found 
no evidence of efficacy [I (PCT)] (Stein et al., 2001). A small 
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placebo-controlled study of the augmentation of paroxetine 
with clonazepam found the combination was marginally short 
of superiority, when compared to paroxetine alone [I (PCT)] 
(Seedat and Stein, 2004).
Recommendations: managing patients with social anx-
iety disorder
Detection and diagnosis
● Become familiar with the symptoms and signs of social 
anxiety disorder [S]
● Assess the level of distress and disability to help distin-
guish social anxiety disorder from shyness [A]
● Ask about the presence of coexisting depressive symp-
toms [A]
● Ask about social anxiety symptoms when patients pre-
sent with depression, panic attacks restricted to social 
situations, or alcohol and cannabis misuse [A]
Acute treatment
● Choose an evidence-based acute treatment [A]
○ pharmacological: most SSRIs (escitalopram, fluoxe-
tine, fluvoxamine, paroxetine, sertraline), venlafaxine, 
phenelzine, moclobemide, some benzodiazepines 
(bromazepam, clonazepam) and anticonvulsants 
(gabapentin, pregabalin), and olanzapine 
○ psychological: cognitive-behaviour therapy
● Avoid prescribing atenolol or buspirone in generalised 
social anxiety disorder [A]
● Take account of patient clinical features, needs and pref-
erence and local service availability when choosing treat-
ment, as pharmacological and psychological approaches 
have broadly similar efficacy in acute treatment [S]
● Consider an SSRI for first-line pharmacological treat-
ment [A]
● Routine prescription of higher doses of SSRIs is not 
recommended [A], but individual patients may benefit 
from higher doses [D]
● Advise the patient that treatment periods of up to 12 
weeks may be needed to assess efficacy [A]
Longer-term treatment
● Use an approach that is known to be efficacious in pre-
venting relapse [S]
● Continue drug treatment for at least six months in 
patients who have responded to treatment [A]
● Consider cognitive therapy with exposure as this may 
reduce relapse rates better than drug treatment [A]
● Consider cognitive therapy after response to drug treat-
ment, in patients with a high risk of relapse [D]
● Monitor effectiveness and acceptability regularly over 
the course of treatment [S]
Combination of drugs and psychological treatment
● Routinely combining drug and psychological approaches 
is not recommended for initial treatment in the absence 
of consistent evidence for enhanced efficacy over 
each treatment when given alone [A]
When initial treatments fail
● Consider raising the dosage if the current dosage is 
well tolerated [D]
● Consider switching to another evidence-based treat-
ment [D]
● Consider combining evidence-based treatments only 
when there are no contraindications [S]
● Consider adding buspirone after partial response to an 
SSRI [C]
● Consider combining evidence-based pharmacological 
and psychological treatments [A]
● Consider benzodiazepines in patients who have not 
responded to other approaches [D]
● Consider referral to regional or national specialist ser-
vices in treatment refractory patients [S]
20. Management of post-traumatic 
stress disorder
20.1. Recognition and diagnosis
Exposure to potentially life-damaging traumatic events is com-
mon, in both genders, during childhood, adolescence and adult life 
[IV] (Nemeroff et al., 2006): but only a proportion of those exposed 
to trauma develop psychological sequelae. For example, the US 
National Comorbidity Survey found that 60.7% of men and 51.2% 
of women reported exposure to at least one traumatic event, but 
post-traumatic stress disorder had a lifetime prevalence of 7.8% [I] 
(Kessler et al., 1995). In the UK, post-traumatic stress disorder was 
present in only a minority of individuals exposed to motor vehicle 
accidents, at three-month (11%) and 12-month (5%) follow-up [I] 
(Mayou et al., 2001). The 12-month prevalence of post-traumatic 
stress disorder is estimated to be 1.1–2.9%, being more common in 
younger than older adults [I] (Wittchen et al., 2011).
Post-traumatic stress disorder shows considerable co-morbid-
ity with other mental disorders [I] (Loewe et al., 2011). Suicidal 
thoughts are common but the increased risk of completed suicide 
is probably due to the presence of comorbid depression [I (M)] 
(Krysinska and Lester, 2010). Post-traumatic stress disorder is 
associated with increased use of health services, but is often not 
recognised in primary or secondary care [I] (Liebschutz et al., 
2007). Diagnosis can be established through eliciting the history 
of exposure to trauma (actual or threatened death, serious injury, 
or threats to the physical integrity of the self or others); with a 
response of intense fear, helplessness or horror; and the presence 
of ‘re-experiencing symptoms’ (such as intrusive recollections, 
flashbacks or dreams); avoidance symptoms (such as efforts to 
avoid activities or thoughts associated with the trauma); and 
hyper-arousal symptoms (including disturbed sleep, hypervigi-
lance and an exaggerated startle response).
20.2. Prevention of post-traumatic disorder 
after experiencing trauma
There is some scope for preventing the emergence of psychologi-
cal post-traumatic symptoms in people subject to major trauma. 
Early administration of benzodiazepines after trauma may not 
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prevent the emergence of post-traumatic symptoms [III] (Gelpin 
et al., 1996). A small randomised placebo-controlled study found 
that acute administration of propranolol (160 mg/day) was supe-
rior to placebo in reducing subsequent post-traumatic symptoms 
and physiological hyper-activity to reminders of trauma, but not 
the emergence of post-traumatic stress disorder, at one month [I 
(PCT)] (Pitman et al., 2002). A naturalistic study suggests acute 
administration of propranolol (120 mg/day) prevented the emer-
gence of syndromal post-traumatic stress disorder at two months 
[III] (Vaiva et al., 2003): but not all evidence is consistent [I 
(PCT)] (Nugent et al., 2010, Stein et al., 2007b). Intravenous 
administration of hydrocortisone has been found superior to pla-
cebo in preventing post-traumatic symptoms, in intensive care 
adult patients with septic shock (median interval, 31 months) [I 
(PCT)] (Schelling et al., 2001), in patients undergoing cardiac 
surgery (interval, six months) [I (PCT)] (Schelling et al., 2004), 
and in patients experiencing acute stress reactions following a 
range of traumatic experiences [I (PCT)] (Zohar et al., 2011). The 
findings of small randomised placebo-controlled treatment stud-
ies find evidence for the efficacy for sertraline [I (PCT)] 
(Stoddard et al., 2011), but not for gabapentin [I (PCT)] (Stein 
et al., 2007b) or escitalopram [I (PCT)] (Shalev et al., 2012), in 
preventing post-traumatic symptoms. The findings of systematic 
reviews suggest that trauma-focused CBT is potentially benefi-
cial in preventing chronic post-traumatic symptoms, when pro-
vided within six months of the incident [I (M)] (Roberts et al., 
2009); but approaches with limited efficacy include single-ses-
sion ‘debriefing’ [I (M)] (Van Emmerik et al., 2002) and multi-
ple-session early intervention [I (M)] (Roberts et al., 2009).
20.3. Acute treatment of post-traumatic 
disorder
The findings of randomised placebo-controlled treatment studies 
indicate that there is evidence for the efficacy of a range of anti-
depressants including some SSRIs (fluoxetine, paroxetine, ser-
traline), amitriptyline, imipramine, mirtazapine, nefazodone, 
phenelzine and venlafaxine (Ipser and Stein, 2011). There is also 
evidence for the efficacy of the antipsychotics risperidone 
(Padala et al., 2006), olanzapine (Carey et al., 2012) and the anti-
convulsant topiramate; (Yeh et al., 2011). Medications which 
have not been found efficacious in placebo-controlled trials 
include citalopram, alprazolam, and the anticonvulsants tiagabine 
and divalproex. However when 37 randomised placebo-con-
trolled trials are subject to meta-analysis (restricted to compari-
sons of outcome data using validated scales), only paroxetine, 
sertraline and venlafaxine were found to have superiority over 
placebo [I (M)] (Ipser and Stein, 2011). Probably due to the small 
size of certain patient sub-groups (men vs women, civilians vs 
military veterans) neither paroxetine nor sertraline have been 
found consistently beneficial across all patient groups: though a 
post hoc analysis suggests that venlafaxine is potentially effica-
cious in reducing post-traumatic symptom severity in men and 
women, and across all trauma types [I (PCT)] (Rothbaum et al., 
2008a). There have been few controlled comparisons of the 
effectiveness and acceptability of differing medications, though 
venlafaxine was found superior to placebo, when sertraline was 
not [I (PCT)] (Davidson et al., 2006b); reboxetine had similar 
effectiveness but lower overall tolerability than fluvoxamine [II] 
(Spivak et al., 2006); and mirtazapine had somewhat greater than 
effectiveness than sertraline, in a randomised but ‘open’ trial [II] 
(Chung et al., 2004).
20.4. Longer term treatment
Although many patients with post-traumatic stress disorder expe-
rience a prolonged illness, there is some uncertainty about the 
course of the condition, as most longitudinal studies in post-trau-
matic stress disorder are retrospective in design. Few prospective 
studies have been published, although the findings of a prospec-
tive study in adolescents and young adults with post-traumatic 
stress disorder or sub-threshold post-traumatic stress disorder 
indicate that around 50% will experience a chronic course of ill-
ness [I] (Perkonigg et al., 2005). The findings of acute and con-
tinuation treatment studies indicate that the proportion of 
responding patients increases steadily over time (Davidson et al., 
2006a; Ipser and Stein, 2011; Londborg et al., 2001). A small 
number of randomised double-blind placebo-controlled relapse 
prevention studies find evidence for the efficacy of longer-term 
treatment, for fluoxetine [I (PCT)] (Martenyi et al., 2002) and 
sertraline [I (PCT)] (Davidson et al., 2005), but not tiagabine [I 
(PCT)] (Connor et al., 2006).
20.5. Comparative efficacy of 
pharmacological, psychological and 
combination treatments
Meta-analyses demonstrate that trauma-focused CBT and eye 
movement desensitisation and reprocessing (EMDR) are both 
efficacious and superior to ‘stress management’ [I (M)] (Bisson 
and Andrew, 2007), and appear to have similar overall efficacy [I 
(M)] (Seidler and Wagner, 2006). There have been very few direct 
comparisons of the efficacy of psychological and pharmacologi-
cal treatments, in either acute or long-term treatment of patients 
with post-traumatic stress disorder. A small unblinded 12-week 
comparison of paroxetine and trauma-focused CBT [III] 
(Frommberger et al., 2004) suggested that CBT may have certain 
advantages, in reducing the severity of post-traumatic and depres-
sive symptoms. A systematic review of four studies of the combi-
nation of pharmacological with psychological treatments could 
find insufficient evidence to draw conclusions about the relative 
efficacy of combination treatment compared to monotherapy [I 
(M)] (Hetrick et al., 2010), although a more recent randomised 
placebo-controlled trial found evidence that paroxetine could 
enhance the effectiveness of prolonged (10 sessions) exposure 
therapy [I (PCT)] (Schneier et al., 2012). The findings of two ran-
domised placebo-controlled studies of the potential augmenta-
tion of exposure therapy through administration of d-cycloserine 
could find no evidence of increased efficacy [I (PCT)] (De 
Kleine et al., 2012; Litz et al., 2012). The findings of two small 
exploratory randomised placebo-controlled trials in patients 
with treatment-resistant post-traumatic stress disorder suggest 
that the short-term efficacy of psychological treatment may be 
enhanced through concurrent administration of 3,4-methylene-
dioxymethamphetamine (MDMA) [I (PCT)] (Mithoefer et al., 
2011; Oehen et al., 2013): with some evidence of persisting 
improvement at two-year follow-up [III] (Mithoefer et al., 2013).
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20.6. Further management after non-
response to initial treatment
Many patients with post-traumatic stress disorder do not respond 
to initial pharmacological or psychological treatment. Switching 
between treatments with proven efficacy may be beneficial [IV] 
(National Institute for Clinical Excellence (NICE), 2005). The 
findings of small randomised placebo-controlled augmentation 
studies provide evidence for the efficacy of the alpha-adrenergic 
agonist prazosin in reducing nightmares and other PSTD symp-
toms [I (PCT)] (Raskind et al., 2003), for olanzapine in reducing 
post-traumatic and depressive symptoms and sleep disturbance [I 
(PCT)] (Stein et al., 2002b) and risperidone in reducing comor-
bid ‘psychotic symptoms’ [I (PCT)] (Hamner et al., 2003), in 
reducing irritable aggression [I (PCT)] (Monnelly et al., 2003), 
and in reducing overall post-traumatic symptoms [I (PCT)] 
(Bartzokis et al., 2005; Rothbaum et al., 2008b). However a large 
randomised placebo-controlled trial found no evidence of benefit 
for risperidone augmentation of a range of pharmacological and 
psychological treatments [I (PCT)] (Krystal et al., 2011).
Recommendations: managing patients with post- 
traumatic stress disorder
Detection and diagnosis
● Ask about a history of traumatic events when patients 
present with psychological symptoms [S]
● Become familiar with the symptoms and signs of post-
traumatic stress disorder [S]
● Ask about the presence of coexisting depressive 
symptoms [A]
Prevention of post-traumatic symptoms
● After major trauma, discuss the potential for preventing 
the emergence of post-traumatic symptoms, and provid-
ing there are no contra-indications, consider preventive 
treatment with propranolol or sertraline [A] or trauma-
focused CBT [A]
● Do not recommend routine single-session or multiple-
session ‘debriefing’ [A]
Acute treatment of chronic post-traumatic stress disorder
● Choose an evidence-based acute treatment [A]
○ pharmacological: paroxetine, sertraline, venlafaxine [A]
○ psychological: trauma-focused individual CBT or 
EMDR [A]
● Consider an SSRI for first-line pharmacological treat-
ment [A]
● Take account of patient clinical features, needs and 
preference and local service availability when choos-
ing treatment, as the comparative efficacy of drug and 
psychological approaches is not established [S]
● Advise the patient that treatment periods of up to 12 
weeks may be needed to assess efficacy [A].
Longer-term treatment
● Use an approach that is known to be efficacious in pre-
venting relapse [S]
● Continue drug treatment for at least 12 months in 
patients who have responded to treatment [A]
● Monitor effectiveness and acceptability regularly over 
the course of treatment [S]
Combination of drugs with psychological treatment
● Routinely combining drug and psychological approaches 
is not recommended for initial treatment in the absence 
of consistent evidence for enhanced efficacy over each 
treatment when given alone [A]: but paroxetine may 
enhance the effectiveness of exposure therapy [A]
When initial treatments fail
● Consider raising the dosage if the current dosage is 
well tolerated [D]
● Consider switching to another evidence-based treatment [D]
● Consider combining evidence-based treatments only 
when there are no contraindications [S]
● Consider combining evidence-based pharmacological 
and psychological treatments [A]
● Consider augmentation of antidepressants with olan-
zapine [A] risperidone [A] or prazosin [A]
● Consider referral to regional or national specialist ser-
vices in treatment refractory patients [S]
21. Management of obsessive-
compulsive disorder
21.1. Recognition and diagnosis
Obsessive-compulsive disorder has an estimated 12-month prev-
alence of 0.7–1.0% [I] (Kessler et al., 2012; Wittchen et al., 
2011), and an estimated lifetime morbid risk of 2.7% [I] (Kessler 
et al., 2012). The female preponderance, early age of onset and 
typical presence of coexisting obsessions and compulsions are 
common features across societies, but the content of obsessions 
varies between cultures [I (M)] (Fontenelle et al., 2004). The dis-
order usually follows a chronic course, waxing and waning in 
severity; and has substantial co-morbidity with major depression 
and anxiety disorders [IV] (Zaudig, 2011), and with tic disorders 
[I] (Fibbe et al., 2012). Distinguishing obsessive-compulsive dis-
order from obsessive-compulsive personality disorder is diffi-
cult, and patients often fulfil diagnostic criteria for both 
conditions: their comorbidity is associated with greater illness 
severity [I] (Coles et al., 2008; Garyfallos et al., 2010; Lochner 
et al., 2011). Patients often present with symptoms arising from 
the co-morbid conditions, rather than with obsessional rumina-
tions and compulsive rituals [I] (Torres et al., 2007).
21.2. Acute treatment of obsessive-
compulsive disorder
The findings of systematic reviews and meta-analyses of ran-
domised double-blind placebo-controlled trials indicate that the 
TCA antidepressant clomipramine, and the SSRIs (citalopram, 
escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline) [I 
(M)] (Soomro et al., 2008) are all efficacious in acute treatment, in 
reducing symptom severity and in improving health-related quality 
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of life [IV] (Fineberg et al., 2012). Pharmacological approaches 
are efficacious in treating children and adolescents with obsessive-
compulsive disorder [I (M)] (Watson and Rees, 2008).
There have been few evaluations of the relative efficacy and 
tolerability of differing pharmacological treatments. The findings 
of meta-analysis suggest that the efficacy of clomipramine is on 
the margins of superiority over that of SSRIs [I (M)] (Ackerman 
and Greenland, 2002; National Institute for Health and Clinical 
Excellence, 2005) but in randomised controlled trials the tolerabil-
ity of SSRIs is generally superior [IV] (Fineberg and Gale, 2005). 
The findings of a randomised comparator controlled trial suggest 
that paroxetine and venlafaxine had comparable effectiveness and 
acceptability [II] (Denys et al., 2003). Fixed-dose randomised con-
trolled studies provide inconsistent evidence for a dose-response 
relationship with SSRIs, higher doses being associated with greater 
overall efficacy in some but not all studies: however the findings of 
meta-analysis of nine treatment studies involving SSRIs finds 
some evidence for greater efficacy (though poorer tolerability) 
with higher daily dosages [I (M)] (Bloch et al., 2010).
Meta-analyses of controlled studies involving psychologi-
cal treatment approaches find evidence for the efficacy of 
behaviour therapy based on exposure with response prevention 
alone, for cognitive restructuring alone, and for exposure with 
response prevention plus cognitive restructuring [I (M)] (Rosa-
Alcazar et al., 2008). Internet-delivered CBT is superior to 
online supportive therapy [I (PCT)] (Andersson et al., 2012), 
though therapist-led CBT appears more effective than comput-
erised CBT [I (M)] (Tumur et al., 2007). The relative effective-
ness of individual and group CBT approaches is uncertain [I 
(M)] (Jonsson and Hougaard, 2009). Psychological approaches 
are efficacious in treating children and adolescents with obses-
sive-compulsive disorder [I (M)] (Watson and Rees, 2008).
21.3. Longer term treatment
The findings of acute treatment studies indicate that the proportion 
of responding patients increases steadily over time. Long-term (up 
to 12 months) double-blind randomised controlled studies demon-
strate an advantage for continuing with medication, in patients who 
have responded to acute treatment [I (PCT)] (Greist et al., 1995; 
Katz et al., 1990; Tollefson et al., 1994). A randomised placebo-
controlled trial with paroxetine as an active comparator found that 
a low dosage of escitalopram only became efficacious in the sec-
ond half of a 24-week study [I (PCT)] (Stein et al., 2007a). Most 
(but not all) placebo-controlled relapse-prevention studies in 
patients who have responded to previous acute treatment reveal a 
significant advantage for staying on active medication (escitalo-
pram, fluoxetine at higher daily doses, paroxetine, sertraline), 
compared with switching to placebo, for up to 12 months [I (PCT)] 
(Fineberg et al., 2007), but the optimal duration of continuation 
treatment is uncertain [I (M)] (Donovan et al., 2010).
21.4. Comparative efficacy of 
pharmacological, psychological and 
combination treatments
It is probable, but not certain, that the combination of pharmaco-
logical and psychological treatment is superior to psychological 
approaches or medication, when either is given alone. The evi-
dence for enhanced efficacy of exposure therapy with clomi-
pramine compared with exposure alone is inconsistent (Foa 
et al., 2005; Marks et al., 1988; Rachman et al., 1979), though 
fluvoxamine has been shown to enhance the efficacy of expo-
sure therapy [I (PCT)] (Cottraux et al., 1990) and multi-modal 
CBT [I (PCT)] (Hohagen et al., 1998). The combination of expo-
sure and response prevention with varying SSRIs has been found 
superior to SSRI treatment alone [II] (Simpson et al., 2008); the 
addition of behaviour therapy after completion of acute treat-
ment was superior to continuing with SSRI treatment alone in 
another study [II] (Tenneij et al., 2005); and the addition of CBT 
(but not CBT instructions) to SSRI treatment was found superior 
to medication management alone, in children and adolescents 
[II] (Franklin et al., 2011). However the value of combination 
treatment over psychological or pharmacological treatments 
given alone over the long term is uncertain. A series of small 
randomised placebo-controlled studies suggest that administra-
tion of d-cycloserine may hasten the response to CBT, but pro-
vide no evidence that the overall effectiveness of CBT is 
enhanced [I (PCT)] (Kushner et al., 2007; Storch et al., 2010; 
Wilhelm et al., 2008).
21.5. Further management after non-
response to initial treatment
Many patients do not respond to first-line pharmacological or 
psychological interventions. Switching between pharmacologi-
cal or psychological treatments with proven efficacy is helpful in 
some patients. Increasing the dose of an SSRI, sometimes beyond 
formulary limits, may be beneficial (Ninan et al., 2006; Pampaloni 
et al., 2010). A placebo-controlled study found that intravenous 
clomipramine infusion was efficacious after non-response to oral 
clomipramine, but the necessary arrangements limit its useful-
ness in practice [I (PCT)] (Fallon et al., 1998).
The findings of some, but not all, randomised double-blind 
placebo-controlled augmentation studies indicate that the addi-
tion of the antipsychotics aripiprazole, haloperidol, olanzapine, 
quetiapine or risperidone to continuing antidepressant treatment 
can be efficacious in patients who have not responded to initial 
treatment with clomipramine or SSRIs, the evidence currently 
being most strong for augmentation with risperidone [I (M)] 
(Dold et al., 2011). The findings of small randomised placebo-
controlled augmentation studies with 5-HT3 antagonists provide 
evidence for the efficacy of the addition of ondansetron to fluox-
etine [I (PCT)] (Soltani et al., 2010) and for the addition of grani-
setron to fluvoxamine [I (PCT)] (Askari et al., 2012). Three 
relatively small randomised placebo-controlled anticonvulsant 
augmentation studies indicate that the addition of topiramate to 
SSRIs reduces the severity of compulsions [I (PCT)] (Berlin 
et al., 2011), and of obsessive-compulsive symptoms [I (PCT)] 
(Mowla et al., 2010); and the addition of lamotrigine to SSRIs 
reduces the severity of obsessive-compulsive and affective 
symptoms [I (PCT)] (Bruno et al., 2012). The evidence for aug-
mentation with pindolol is mixed, but placebo-controlled or com-
parator-controlled augmentation studies find no evidence for the 
efficacy of augmentation with buspirone, clonazepam, desipra-
mine, inositol, liothyronine, lithium, naltrexone or oxytocin [IV] 
(Fineberg and Gale, 2005).
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The findings of a randomised comparator-controlled trial of 
dextroamphetamine or caffeine augmentation of SSRI or SNRI 
antidepressants suggest both compounds were beneficial in 
reducing symptom severity [II] (Koran et al., 2009). Other 
potential but as yet unproven approaches in the management of 
patients with treatment-resistant obsessive-compulsive disorder 
include monotherapy with once-weekly morphine [I (PCT)] 
(Koran et al., 2005); and the glutamate-modulating compounds 
riluzole [III] (Coric et al., 2005; Pittenger et al., 2008), meman-
tine [III] (Stewart et al., 2010), and glycine [I (PCT)(Greenberg 
et al., 2009). Some patients with treatment-refractory obses-
sive-compulsive disorder may benefit from deep brain stimula-
tion and other neurosurgical approaches [IV] (Blomstedt et al., 
2012; De Koning et al., 2011; Greenberg et al., 2010).
Recommendations: managing patients with obsessive-
compulsive disorder
Detection and diagnosis
● Become familiar with the symptoms and signs of 
obsessive-compulsive disorder [S]
● Assess the time engaged in obsessive-compulsive behav-
iour, the associated distress and impairment, and the 
degree of attempted resistance to confirm the diagnosis [S]
● Ask about obsessive-compulsive symptoms when 
patients present with depression [S]
● Ask about the presence of coexisting depressive symp-
toms [A]
Acute treatment
● Choose an evidence-based acute treatment [A]
○ pharmacological: clomipramine and all SSRIs [A]
○ psychological: exposure therapy, cognitive-behav-
iour therapy, cognitive therapy [A]
● Take account of patient clinical features, needs and 
preference and local service availability when choos-
ing treatment [S]: drug and psychological approaches 
have broadly similar efficacy in acute treatment
● Consider an SSRI for first-line pharmacological treat-
ment [D]
● Consider increasing the daily dosage of SSRIs if there 
is insufficient response at lower dosage [A]
● Advise the patient that initial treatment periods beyond 
12 weeks may be needed to assess efficacy [A]
Longer-term treatment
● Use an approach that is known to be efficacious in pre-
venting relapse [S]
● Continue drug treatment for at least 12 months in 
patients who have responded to treatment [A]
● Monitor effectiveness and acceptability regularly over 
the course of treatment [S]
Combination of drugs with psychological treatments
● Consider combining an SSRI or clomipramine with an 
evidence-based psychological treatment when efficacy 
needs to be maximised [D]
When initial treatments fail
● Consider raising the dosage if the current dosage is 
well tolerated [A]
● Consider switching to another evidence-based treat-
ment [D]
● Consider combining evidence-based treatments only 
when there are no contraindications [S]
● Consider combining evidence-based pharmacological 
and psychological treatments [A]
● Consider augmentation of an SSRI or clomipramine 
with an antipsychotic drug [A]
● Consider augmentation of an SSRI or clomipramine 
with a 5-HT3 antagonist [A]
● Consider augmentation of an SSRI with topiramate [A] 
or lamotrigine [A]
● Consider augmentation of an SSRI with morphine [A]
● Consider augmentation of an SSRI with riluzole [C]
● Consider referral to regional or national specialist 
obsessive-compulsive disorder services in treatment 
refractory patients [S]
22. Management of other anxiety 
disorders
22.1. Marked health anxiety (‘illness anxiety 
disorder’)
The DSM-5 ((American Psychiatric Association, 2013) includes 
‘illness anxiety disorder’ within the group of ‘somatic symptom 
and related disorders’. The condition is characterised by excessive 
concern over health, constant fear of undiagnosed disease that phy-
sicians may have missed, and the characteristic behaviours of 
repeated checking and need for medical reassurance. 
Pharmacological treatment is not normally acceptable to patients, 
as those with marked health anxiety are typically very sensitive to 
adverse effects of medication: but fluoxetine showed some benefit 
over placebo, though this was not pronounced and occurred late in 
treatment (8–12 weeks [I (PCT)] (Fallon et al., 2008). Psychological 
treatments have been found beneficial [I (M)] (Thomson and Page, 
2007), and include behavioural stress management (Clark et al., 
1998) ([II]), cognitive behaviour therapy, in both face-to-face and 
internet format (Hedman et al., 2011b; Seivewright et al., 2008; 
Sørensen et al., 2011) ([II]), and mindfulness –based CBT 
(McManus et al., 2012) ([II]). A recent large randomised controlled 
trial found efficacy for an adapted form of CBT in medical patients, 
in which significant benefits over standard care were still present 
two years after therapy had ended [II] (Tyrer et al., 2014).
22.2 Separation anxiety disorder in adults
Though traditionally regarded as having an onset in childhood, 
separation anxiety disorder is now recognised as both continuing 
into and having an onset during adult life: and as such is grouped 
with other anxiety disorders within the DSM-5 (American 
Psychiatric Association, 2013). The efficacy of psychological or 
pharmacological treatment in adults with separation anxiety 
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disorder has not been studied extensively, and treatment studies in 
children have often involved mixed diagnostic groups [IV] (Bögels 
et al., 2013). Psychological treatment studies in children find some 
evidence of benefit with CBT, parent-child interaction training, 
and ‘summer camp’ programmes [IV] (Ehrenreich et al., 2008). 
The findings of randomised placebo-controlled trials of pharmaco-
logical treatment in children with separation anxiety disorder pro-
vide no convincing evidence of benefit for any medication, 
although fluvoxamine (Walkup et al., 2001) and sertraline have 
been found efficacious among the separation anxiety disorder sub-
group within mixed diagnostic samples (Walkup et al., 2008).
Recommendations: treatment of children and 
adolescents
● Reserve pharmacological treatments for children and 
teenagers who have not responded to psychological 
interventions, and in whom the anticipated benefits are 
expected to outweigh any potential risks [S]
● Choose from the same range of treatments as considered 
for adult patients, considering an SSRI for first-line 
pharmacological treatment: fluoxetine may be the SSRI 
with the best balance of potential benefit and risk [B]
● Ensure that the daily dosage takes account of the age 
and weight of the patient, and start with low dosage, 
recognising that more rapid metabolism may lead to 
the need for ‘adult’ doses [S]
● Monitor patients carefully, especially for any evidence 
of increased anxiety and agitation, and remember that 
many children and adolescents find it hard to describe 
emotional states and possible psychological adverse 
effects [D]
23. Special considerations in 
particular patient groups
23.1. Children and adolescents
When compared with investigations in individuals aged between 
18–65 years, there have been relatively few randomised placebo-
controlled studies of the potential benefits and risks of psycho-
tropic drug treatment in younger people, and little is known about 
the value of long-term treatment [I (M)] (Ipser et al., 2009). The 
findings of randomised placebo-controlled trials in children and 
adolescents indicate that SSRI treatment can be effective in chil-
dren and adolescents with generalised anxiety disorder, separa-
tion anxiety disorder or social anxiety disorder [I (M)] (Dieleman 
and Ferdinand, 2008), and also in post-traumatic stress disorder 
[IV] (Strawn et al., 2010), and obsessive-compulsive disorder 
[IV] (Gentile, 2011). Psychological treatments also have evi-
dence of efficacy [I (M)] (Gillies et al., 2012; James et al., 2005; 
Kircanski et al., 2011; Kowalik et al., 2011) but the relative effi-
cacy of pharmacological and psychological treatment approaches, 
alone and in combination, is not established: although combina-
tion treatment was found optimal in obsessive-compulsive disor-
der (March et al., 2004).
In 2004, the United Kingdom Committee on Safety of 
Medicines stated that the balance of risks and benefits for the 
treatment of depressive illness in people under the age of 18 years 
was judged to be unfavourable for some SSRIs (escitalopram, cit-
alopram, paroxetine and sertraline), mirtazapine and venlafaxine 
[IV] (Committee on Safety of Medicines, 2004), and advised cau-
tion when treating depressed adults aged 18–30 years with SSRIs. 
A recent meta-analysis cautiously concluded that the balance of 
benefit and risk in the treatment of depressed children and adoles-
cents may be most favourable with fluoxetine [I (M)] (Hetrick 
et al., 2012).
The balance of risks of harm and benefit in the treatment of 
children and adolescents with anxiety disorders, when compared 
to the treatment of depression, is more favourable [IV] (Holtkamp 
and Herpertz-Dahlmann, 2008). However careful monitoring is 
advisable, due to possible diagnostic uncertainty, the presence of 
co-morbid depression, problems associated with estimating the 
optimal dosage, and the difficulties young people might have in 
describing untoward effects of psychotropic drug treatment. It 
may be preferable to reserve pharmacological treatments for 
patients who do not respond to evidence-based psychological 
approaches.
23.2. Elderly patients and patients with 
cardiac or neurological disease
Many elderly patients are troubled by anxiety symptoms, but 
anxiety disorders in those over 65 years may be less common 
than in younger age groups [IV] (Wolitzky-Taylor et al., 2010). 
When compared with investigations in individuals aged between 
18–65 years, there have been relatively few randomised con-
trolled studies of the potential benefits and risks of psychological 
or pharmacological treatment for anxiety disorders in older peo-
ple [IV] (Oude Voshaar, 2013), and little is known about the rela-
tive effectiveness and acceptability of differing treatments, or 
about the value of long-term treatment [I (M)] (Goncalves and 
Byrne, 2012; Gould et al., 2012; Pinquart and Duberstein, 2007; 
Thorp et al., 2009). Clearance of many drugs is slower in the 
elderly, so lower doses may be required than in younger patients.
Tricyclic antidepressants and some antipsychotic drugs are 
best avoided in patients with cardiac disease, as they can increase 
heart rate, induce orthostatic hypotension, slow cardiac conduc-
tion and have significant quinidine-like effects on conduction 
within the myocardium [IV] (Vieweg et al., 2009). Other type 1A 
antiarrhythmics (quinidine, moricizine) carry an increased risk of 
mortality in patients with ventricular arrhythmias and ischaemic 
heart disease, and TCAs should be regarded as relatively contrain-
dicated in these situations. SSRIs have relatively minor effects on 
cardiovascular function and may have potentially beneficial 
effects on platelet aggregation (Bismuth-Evenzal et al., 2012; 
Lopez-Vilchez et al., 2009). Higher doses (more than 40 mg per 
day) of citalopram may be associated with a slightly increased risk 
of QT interval prolongation on the electrocardiogram, and should 
be avoided in patients with known cardiac risk factors including 
hypokalaemia and hypomagnesaemia [IV] (US Food and Drug 
Administration, 2012): though a recent large pharmacoepidemio-
logical study found no evidence of elevated risks of ventricular 
arrhythmia or all-cause, cardiac or non-cardiac mortality associ-
ated with higher citalopram dosages [I] (Zivin et al., 2013).
Anxiety symptoms and disorders have an increased prevalence 
in patients with common neurological conditions, including 
migraine [IV] (Buse et al., 2012), epilepsy [IV] (Beyenburg et al., 
2005), and in the aftermath of stroke [I (M)] (Campbell Burton 
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et al., 2012). SSRI and SNRI antidepressants should be used with 
caution in patients with migraine undergoing prophylaxis with 
triptans [IV] (Evans et al., 2010). Despite widespread belief that 
antidepressant drugs can lower the seizure threshold, systematic 
review of data from placebo-controlled trials with psychotropic 
drugs, submitted to the United States Federal Drug Administration, 
indicates that that the frequency of seizures is significantly lower 
with most antidepressants than with placebo [I (M)] (Alper et al., 
2007).  Pharmacokinetic interactions between medications used 
for treating anxiety disorders and anticonvulsants are not uncom-
mon and it is always advisable to establish the potential for unto-
ward drug-drug interactions when treating epileptic patients with 
anxiety disorders [IV] (Muscatello et al., 2012). SSRI treatment 
may improve overall recovery after stroke [I (M)] (Mead et al., 
2012), but little is known about the potential efficacy of psycho-
logical or pharmacological interventions in the treatment of anxi-
ety disorders in the aftermath of stroke [I (M)] (Campbell Burton 
et al., 2011).
Recommendations: treatment in elderly and physically 
ill patients
● Remember that anxiety symptoms and disorders are 
common in elderly and physically ill patients, and that 
many individuals will benefit from evidence-based 
pharmacological or psychological treatments [S]
● Manage elderly patients in a broadly similar way to 
younger patients, being mindful of the possibility of 
drug interactions, the potential need for lower doses in 
patients with renal or hepatic impairment, and the risk of 
worsening any pre-existing cognitive impairment 
through the use of medications with sedative effects [S]
● Avoid prescribing tricyclic antidepressants to patients 
with cardiovascular disease [D]
23.3. Pregnant and breastfeeding women
Anxiety disorders are not uncommon during pregnancy and in 
the post-partum period [I (M)] (Ross and McLean, 2006). 
Symptoms will remit during pregnancy in some women [III] 
(George et al., 1987). Many doctors consider the scope for with-
drawing psychotropic drugs in pregnant women (particularly in 
the first trimester), and using psychological rather than pharma-
cological treatments, but in practice it is sometimes necessary to 
continue pharmacological treatment, in patients with severe 
anxiety disorders. The findings of a recent systematic review 
indicate that antidepressant drugs are associated with increased 
risk of spontaneous abortions, stillbirths, preterm deliveries, res-
piratory distress, endocrine and metabolic disturbance, with 
some evidence of a discontinuation syndrome and of an increased 
risk of cardiac defects; antipsychotics are associated with 
increased gestational weight and diabetes and with increased 
risk of preterm birth [I (M)] (Oyebode et al., 2012). However the 
overall evidence on the balance of risks and benefits of psycho-
tropic drug treatment during pregnancy evolves over time and it 
is wise to seek advice from respected information sources. The 
BAP is producing guidance on the management of patients dur-
ing the perinatal period (McAllister-Williams et al., in 
development). 
Recommendations: women of child-bearing age
● Remember that anxiety disorders are common among 
women who wish to become pregnant [S]
● Keep familiar with the changing evidence base about 
the potential hazards of treatment of pregnant and 
breast-feeding women with psychotropic drugs [S]
● Consider carefully the anticipated benefits and risks of 
pharmacological and psychological treatments of anxi-
ety disorders in pregnant women, including the poten-
tial relative and actual risks of harm to a developing 
child [S]
23.4. Referral to secondary and tertiary care 
mental health services
Despite the availability of many evidence-based pharmacologi-
cal and psychological treatments, a substantial proportion of 
patients will not respond fully to initial treatments, provided in 
primary medical care. The criteria for referral to secondary care 
mental health services should be sufficiently flexible to ensure 
that patients with disabling and treatment-resistant anxiety disor-
ders can have equitable access to mental health specialists. 
Consensus between primary and secondary care about when 
referral of patients with anxiety disorders is advisable should be 
an explicit component of service commissioning procedures. 
Potential criteria for referral to secondary care mental health ser-
vices include when the primary care practitioner feels insuffi-
ciently experienced to manage the patient’s condition; when two 
or more attempts at treatment have not resulted in sustained 
improvement; when there are severe coexisting depressive symp-
toms or a risk of suicide; when comorbid physical illness and 
concomitantly prescribed treatments could interact with pre-
scribed psychotropic medication; and when proposed interven-
tions are not available within primary care services. Some 
patients with complex, severe, enduring and treatment-resistant 
anxiety disorders do not respond to the range of treatment options 
delivered in secondary care mental health services, and these 
patients should be referred to tertiary care specialist services for 
patients with affective disorders.
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